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ABSTRACT

Stem cell biology is an exciting field that will lead to significant
advancements in science and medicine. We hypothesize that inducing the
expression of stem cell genes, using the embryonic stem cell gene nanog, will
reprogram cells and dedifferentiate human mesenchymal stem cells into
pluripotent stem cells capable of neural differentiation. The aims of initial
studies are as follows:
Aim 1: Demonstrate that forced expression of the embryonic stem cell
gene nanog induces changes in human mesenchymal stem cells to an
embryonic stem cell-like phenotype.
Aim 2: Demonstrate that induced expression of nanog up-regulates the
expression of multiple embryonic stem cell markers and expands the
differentiation potential of the stem cells.
Aim 3: Demonstrate that these nanog-expressing stem cells have the
ability to differentiate along neural lineages in vitro and in vivo, while mocktransfected cells have an extremely limited capacity for transdifferentiation.
Alternatively, we hypothesize that embryonic stem cell genes can
become activated in malignant gliomas and differentially regulate the
subpopulation of cancer stem cells. This study examines the role of
embryonic stem cell genes in transformed cells, particularly cancer stem cells.
These studies explore has the following objectives:
Aim 1: Isolate different sub-populations of cells from tumors and
characterize cells with stem cell-like properties.
ii

Aim 2: Characterize the expression of embryonic stem cell markers in
the sub-population of cancer stem cells.
Aim 3: Examine the effects of histone deacetylase inhibitors at
inhibiting the growth and reducing the expression of stem cell markers.
Our research has demonstrated the potential of the embryonic
transcription factor, nanog, at inducing dedifferentiation of human bone
marrow mesenchymal stem cells and allowing their recommitment to a neural
lineage. Specifically, we used viral and non-viral vectors to induce expression
of NANOG, which produced an embryonic stem cell-like morphology in
transduced cells. We characterized these cells using real-time PCR and
immunohistochemical staining and find an up-regulation of genes responsible
for pluripotency and self-renewal. Embryonic stem cell markers including
Sox2, Oct4 and TERT were up-regulated following delivery of nanog. The role
of nanog in the expression of these markers was further demonstrated in our
induced-differentiation method where we transfected embryonic stem cell-like
cells, that have been transduced with nanog flanked by two loxP sites, with a
vector containing Cre-recominase. We tested the ability of these nanogtransfected cells to undergo neural differentiation in vitro using a neural coculture system or in vivo following intracranial transplantation.
Our next study characterized patient-derived glioblastoma cancer stem
cells. We found that cells isolated from serum-free stem cell cultures were
enriched for stem cell markers and were more proliferative than the bulk
population of cells grown in convention serum-supplemented media. These
cancer stem cells expressed embryonic stem cell markers NANOG and OCT4
iii

whereas non-tumor-derived neural stem cells do not. Moreover, the
expression of stem cell markers was correlated with enhanced proliferation
and could serve as a measure of drug effectiveness. We tested two different
histone deacetylase inhibitors, trichostatin A and valproic acid, and found that
both inhibited proliferation and significantly reduced expression of stem cell
markers in our cancer stem cell lines. These data demonstrate the potential
use of stem cell genes as therapeutic markers and supports the hypothesis
that cancer stem cells are a major contributor to brain tumor malignancy.

iv

TABLE OF CONTENTS

LIST OF FIGURES ........................................................................................ viii
LIST OF TABLES........................................................................................... xiii
LIST OF ABBREVIATIONS .......................................................................... xiv
CHAPTER ONE: NANOG OVEREXPRESSION ALLOWS HUMAN
MESENCHYMAL STEM CELLS TO DIFFERENTIATE INTO NEURAL
CELLS ............................................................................................................. 1
Chapter Summary ....................................................................................... 1
Introduction .................................................................................................. 2
Materials and Methods ................................................................................ 4
Cell Culture ............................................................................................. 4
Cloning of Nanog Gene ........................................................................... 6
Production of Lentivirus Containing Nanog ............................................. 6
Non-viral and Viral Gene Delivery ........................................................... 7
Gene Expression Analysis ...................................................................... 8
Stem Cell Transplantation ....................................................................... 9
Stem Cell Transplantation ..................................................................... 10
Brain Sample Preparation ..................................................................... 11
Immunocytochemistry and Immunohistochemistry ................................ 12
Results....................................................................................................... 13
Discussion ................................................................................................. 28
Acknowledgement ..................................................................................... 32
CHAPTER TWO: EMBRYONIC STEM CELL MARKERS DISTINGUISH
CANCER STEM CELLS FROM NORMAL HUMAN NEURONAL STEM
CELL POPULATIONS IN MALIGNANT GLIOMA PATIENTS........................ 34
Rationale ................................................................................................... 34
v

Chapter Summary ..................................................................................... 34
Introduction ................................................................................................ 35
Materials and Methods .............................................................................. 38
Cell Culture and Isolation ...................................................................... 38
RNA Isolation and Quantitative Real-Time PCR ................................... 39
cDNA synthesis ..................................................................................... 41
Real-Time PCR ..................................................................................... 41
Immunocytotochemistry ........................................................................ 42
Results....................................................................................................... 43
Discussion ................................................................................................. 51
Conclusions ............................................................................................... 52
CHAPTER THREE: CHARACTERIZATION OF CANCER STEM CELLS
WITHIN GLIOBLASTOMAS AND THEIR INHIBITION W ITH HISTONE
DEACETYLASE INHIBITORS ....................................................................... 54
Rationale ................................................................................................... 54
Chapter Summary ..................................................................................... 55
Introduction ................................................................................................ 56
Materials and Methods .............................................................................. 58
Cell Culture and Isolation ...................................................................... 58
Isolation of Cells from Surgical Aspirate ................................................ 59
Culturing of Human Neural Stem Cell Lines .......................................... 60
Generation of Clonal-Derived Cancer Stem Cell Lines ......................... 60
RNA Isolation and Quantitative Real-Time PCR ................................... 61
Cell Differentiation ................................................................................. 62
Drug Treatments ................................................................................... 62
Immunohistochemical Staining .............................................................. 62
vi

Microscopy ............................................................................................ 64
Statistical Analysis................................................................................. 64
Results....................................................................................................... 65
Isolation of Cancer Stem Cell Lines ...................................................... 65
Gene Expression Analysis of Cancer Stem Cell Lines .......................... 75
Differentiation Analysis of Cancer Stem Cell Lines ............................... 78
Effects of Histone Deacetylase Inhibitors on Cancer Stem Cell
Lines...................................................................................................... 81
Discussion ................................................................................................. 85
Conclusions ............................................................................................... 89
Author Contributions .................................................................................. 89
REFERENCES .............................................................................................. 90

vii

LIST OF FIGURES

Figure 1: (a) HMSCs over-expressing Nanog displayed ESC-like (v-viii)
or EB-like morphology (ix-xii). Morphological changes seen at three
weeks (i,v,ix), two (ii,vi,x), three (iii,vii,xi), and six months (iv,viii,xii) posttransfection. (b) HMSCs nine days post-transduction with Nanog lentivirus (ii). Three weeks following non-viral Nanog transfection (iii) and
three days later (iv). Untreated HMSCs showed as a control (i). ................... 15
Figure 2: (a) RT-PCR shows little or no expression of Nanog and Oct-4 in
mock-transfected HMSCs but up-regulation of both at two, five, and
eleven months following Nanog transfection up to 11 month in a culture.
GAPDH was a control. (b) qRT-PCR of Nanog lentiviral-transduced cells.
Up-regulation of multiple ESC genes after Nanog transfection (grey) were
observed and these genes were down-regulated after (black) delivery of
Cre recombinase vectors to remove Nanog expression. ............................... 18
Figure 3: Immunocytochemistry of Nanog transfected HMSC colonies
showed strong immunoreaction for ES cell markers after15 weeks in a
culture (v-viii) while there is no expres- sion of ES cell markers in mocktransfected HMSCs (i-iv). The cells were immunostained for Nanog (i, v),
Oct-4 (ii, vi), SSEA-3 (iii, vii), and TRA-1-60 (iv, vii). ...................................... 21
Figure 4: With mock-transfected HMSCs showed no ESC- like colony
formation (i,v) nor GFP expressions (ii,vi) and immunoreactivities for
Nanog (iii) and Sox-2 (vii) are not detected. Lentiviral transduction with
Nanog and GFP in- duced colony formation (ix, xiii) and GFP expression
(x, xiv), and positive for Nanog (xi) and Sox-2 (xv) immunore- activities.
DAPI is used counter stain of nuclei (iv, viii, xii, xvi)....................................... 23
Figure 5: After co-culture with differentiated human neural stem cells,
naive HMSCs showed few GFAP (red) but no βIII-tubulin (green)
immunoreactivites (i). While Nanog- transfected HMSCs forming clusters
of cells co-cultured with differentiated human neural stem cells attached
to the culture insert membrane and migrated outward. They were positive
for GFAP (red) and βIII-tubulin (green) immunoreactivites indicating neural
differentiation of the cells, (low magnification in ii, high magnification in iii).
Differentiated Nanog-transfected HMSCs are also stained positive for
MAP2 (green) and S100 (red) at two weeks, indicating differentiation
into mature neurons and astrocytes, respectively. ......................................... 25

viii

Figure 6: After transplantation into mice, Nanog-GFP transfected
HMSCs HMSCs are capable of migration into hippocampus dentate
gyrus (i). Immunostaining specific to human βIII-tubulin (green) and
GFAP (red) indicated that the transplanted Nanog-transfected HMSCs
after Cre recombinase treatment differentiated into neurons and
astrocytes in the dentate gyrus (ii, iii) and CA1 regions (iv) of the
hippocampus, respectively............................................................................. 26
Figure 7: Isolation of cell populations from patient tumor samples.
Cells are isolated from patient samples either by dissociating the bulk
tumor mass using surgical scalpels (a) or through centrifugation of the
surgical aspirate solution (b). Cells isolated from either approach produce
populations of cells that are adherent or form floating spheroids. The
spheroids have the properties of cancer stem cells while the adherent
cells resemble the characteristics of differentiated cells. ............................... 44
Figure 8: Expression of CD133 and BrdU staining between adherent and
floating stem cell cultures. Cells expanded and spheroids had higher
BrdU staining and enriched CD133 staining within the spheroid (A).
Transferring cells to differentiation media supplemented with 10% FBS
for four days reduced the frequency of BrdU-positive cells, but CD133
was still expressed in some of the cells. (B) Although most adherent cells
did not express CD133, some positive cells could still be observed (C).
Scale bar = 63μm........................................................................................... 45
Figure 9: Proliferation rates measured by 48 hour BrdU-treatment
Transferring cancer stem cells in serum-supplemented media reduced
the rates of proliferation by 50% (p<0.001). After 48 hours, only 25% of
adherent line 1 and 13% of adherent line 3 were positive for BrdU
compared to nearly 80% of cancer spheroids (p<0.0001). ............................ 46
Figure 10: Expression of stem cell and differentiation markers in tumorderived stem cells. Tumor-derived cells grow as non-adherent spheroids
display low rates of GFAP and βIII-tubulin expression (A). Tumor spheroids
do readily express stem cell markers Sox2 (B) and Nestin (C). Adherent
cell cultures show stronger staining for neuronal differentiation markers
(MAP2 and βIII-tubulin, D) as well as astrocytic markers (S100 and GFAP,
E). Cancer stem cells could be induced to express both neuronal (F) and
astrocytic (G) markers following one-week differentiation in media
supplemented with retinoic acid. Scale bar = 63μm. ...................................... 47
Figure 11: Expression of embryonic stem cell markers in cancer
spheroids. Sphere forming cells express embryonic stem cell markers
Nanog, SSEA4, Oct4 and CD133. ................................................................. 50

ix

Figure 12: Morphology of cells in culture. Dissociation of tumor tissues
can produce two distinct cell populations, adherent cells that grow in a
monolayer in serum-supplemented culture (A1) or cells that grow in
suspension in NSC culture conditions (A2). Cells isolated from the
surgical flush are also give rise to monolayer (A3) and spheroid-growing
cells (A4), in serum-supplemented and NSC culture media, respectively.
More cellular debris is present with surgical aspirate-derived cultures.
Cells grown in serum-supplemented (B1) and serum-free stem cell media
(B2) maintain their growth patterns in continuous culture (5 weeks).
Tumor-derived cells expanded in serum-free stem cells cultures
resemble fetal-derived non-cancerous stem cells (B3). Scale bar = 63μm. ... 67
Figure 13: Expression of stem cell and lineage markers in the ReNcell
Cx line. The immortalized neural progenitor cell line ReNcell Cx grow
as an attached monolayer in plates pre-coated with laminin. Fixed cells
were treated with DAPI to stain the nuclei (A-E4). They do not show
positive staining when stained with secondary antibodies conjugated
with either FITC (A2) or TRITC (A3). They do demonstrate expression
of lineage markers βIII-tubulin (B2) and GFAP (B3) as well as neural
stem cell markers. ReNcell Cx cells also have positive staining for Nestin
(C2), CD133 (C3), MCM2 (D2), and Sox2 (D3). However, the neural stem
cell line does not stain positive for the embryonic stem cell markers Oct4
(E2) or Nanog (E3). Scale bar = 63μm. ......................................................... 70
Figure 14: Expression of stem cell and lineage markers in adherent
tumor-derived cells. Adherent tumor-derived cells grown in serumsupplemented media do not appreciably express stem cell markers
CD133 (A2) or Oct4 (A3). However, cells do demonstrate strong
expression of the mature neuronal marker MAP2 (B2) as well as the
early lineage marker βIII-tubulin (B3). The cells also have strong
expression of glial differentiation markers S100 (C2) and GFAP (C3).
Scale bar = 63μm........................................................................................... 71
Figure 15: Expression of stem cell markers in tumor-derived stem cells.
Tumor-derived cells grow as non-adherent spheroids express stem
cell markers CD133 (A2, E2), Oct4 (A3), Nestin (B2), Sox2 (B3, D2),
Nanog (C2), SSEA4 (C3) and MCM2 (E3), but not surface marker
TRA1-60 (D3). Scale bar = 63μm. ................................................................. 73
Figure 16: Expression of lineage markers in tumor-derived stem cells.
The cells also expressed developmental markers for neuronal (βIIItubulin (A3) and MAP2 (B2)) and glial (GFAP (A2, C3), S100 (C2))
lineage differentiation. Scale bar = 63μm....................................................... 74

x

Figure 17: Cancer spheroids have enhanced stem cell gene expression
patterns. Cancer spheroids derived from either the bulk of the tumor
tissue (CSC AA1-02 and CSC AA3-01) or the surgical flush (CSC
AA1-06) demonstrate enriched expression of stem cell markers and
other genes compared to adherent tumor cells expanded in serum supplemented cultures. Cancer stem cell line AA1-02 showed elevated
expression of GAPDH and stem cell transcription factors nanog, oct4,
and sox2. Cell lines CSC AA1-06 and CSC AA3-01 show enhanced
expression of stem cell markers nanog and sox2. Telomerase reverse
transcriptase (TERT) and telomeric repeat-binding factor-1 (TERF1)
were both significantly higher in the cancer stem cell lines. The stem cell
genes that showed the greatest differential expression were the stem cell
transcription factors nanog and sox2 along with tert and surface marker
CD133. Statistical significance indicated by asterisks: *p<0.05,
**=p<0.01, ***p<0.001, ****p<0.0001. ............................................................ 76
Figure 18: Differentiation of cancer spheroids. Human neural stem
cells undergo differentiation when transferred to a serum - and growth
factor-free basal medium. Following one week of differentiation in nonsupplemented basal cell culture media, neural stem cell spheroids
adhered to the plate and migrated outward, increasing the expression
of βIII-tubulin (A1) and GFAP (A2), cancer spheroids also expressed βIIItubulin (B1) and GFAP (B2), but were more resistant to differentiation.
Cancer spheroids still expressed stem cell markers CD133 (C1) and Oct4
(C2) after one week of basal media differentiation. Moreover, the
expression of both stem cell markers persisted even when cultured in
basal media supplemented with retinoic acid (D1-3). The use of serumsupplemented media was used to induce differentiation of tumor
spheroids (E1-4). Following four days of serum-induced differentiation,
differentiating cells migrated away from the spheroid and had more
intense staining for βIII-tubulin (E1), but lower staining for CD133 (E2),
Sox2 (E3), and Nanog (E4). Serum-induced differentiation also
significantly decreased proliferation and Sox2 expression. Scale bar
= 63μm. Statistical significance indicated by asterisks: *p<0.05,
**=p<0.01, ***p<0.001, ****p<0.0001. ............................................................ 79
Figure 19: Histone deacetylase inhibitors alter glioma stem cell
morphology. Cancer stem cells proliferate rapidly in culture, yielding
a high frequency of BrdU-stained cells (A2) as well as robust staining
for CD133 (A4). Supplementing the stem cell media with valproic acid
(VPA, 1mM) or trichostatin A (TSA, 1μM) decreased the number of
BrdU-positive cells (BC2) and showed lower CD133 staining (B-C3).
Cells also appear to have more cellular processes after exposure to
either VPA (B) or TSA (C), indicating induction of differentiation. Scale
bar =63μm. .................................................................................................... 82

xi

Figure 20: Valproic acid and trichostatin A reduce glioma stem cell
proliferation. Treatment with 1mM valproic acid significantly reduced
the rate of glioma stem cell proliferation, decreasing the frequency of
BrdU-positive cells from 78% to 60% (p<0.01). Exposure to trichostatin
A had an even more profound reduction in proliferation, reducing the
frequency of cells that underwent proliferation to 34% (p<0.001). ................. 83
Figure 21: Valproic acid and trichostatin A negatively regulate the
expression of stem cell genes. Treatment with histone deacetylase
inhibitors valproic acid and trichostatin A significantly lowered the
expression of stem cell genes while increasing the expression of
lineage differentiation markers. Expression of CD133 and nanog
dramatically reduced when cultured with either VPA or TSA. Valproic
acid inhibited oct4 expression, while TSA reduced levels of sox2. The
embryonic stem cell marker zfp342 was abated by both drugs. TERT
was also diminished by both HDACi, whereas levels of terf1 were not
significantly altered. Interestingly, there were no changes in the levels
of the apoptosis inhibitor Bcl-xL or its repressor Bcl-xs. Culturing with
the drugs did up-regulate differentiation markers βIII-tubulin and GFAP. ...... 84

xii

LIST OF TABLES

Table 1 PCR Analysis of Clones Resistant to Differentiation Relative to
Normal Tumor Non-neurosphere Cells .......................................................... 48
Table 2 Nanog CT Values for GBM Tumor Clones ........................................ 49

xiii

LIST OF ABBREVIATIONS

AD

Alzheimer’s Disease

ANOVA

Analysis of variance

Bcl

B-cell lymphoma

BrdU

Bromodeoxyuridine

°C

Degrees Celcius

c-MYC

avian myelocytomatosis viral oncogene homolog

Ct

Cycle threshold

Cre

Cyclization recombination

CSC

Cancer stem cell

DAPI

4',6-diamidino-2-phenylindole

DMEM

Delbecco's Modified Eagle's Medium

DNA

Deoxyribonucleic acid

EB

embryoid body

EGF

Epidermal growth factor

eGFP

enhanced Green Flourescence Protein

ESC

Embryonic Stem Cell

FBS

Fetal bovine serum

FGF

Fibroblast growth factor

FITC

Fluorescein isothiocyanate

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GBM

Glioblatoma

GFAP

Glial fibrillary acidic protein

h

Human

HDACi

histone deacetylase inhibitors
xiv

HPRT

hypoxanthine- guanine phosphoribosyltransferase

Lox P

Locus of X-over P1

m

Mouse

MAP2

Microtubule-associated protein 2

MCM2

mini-chromosome maintenance protein 2

MSC

Mesenchymal Stem Cell

NSC

Neural Stem Cell

Oct4

Octamer-binding transcription factor 4

PBS

Phosphate-buffered saline

PCR

Polymerase chain reaction

PFA

Paraformaldehyde

RNA

Ribonucleic acid

RT-PCR

Real-time polymerase chain reaction

SD

Standard deviation

Sox2

SRY (sex determining region Y)-box 2

SSEA

Stage-Specific Embryonic Antigen

SV40T

Simian virus large T antigen

TERF1

Telomeric repeat-binding factor 1

TERT

Telomerase reverse transcriptase

TRITC

Tetramethyl Rhodamine Isothiocyanate

TSA

Trichostatin A

UTR

Un-translated region

VPA

Valproic Acid

VSV-G

Vesicular stomatitis virus glycoprotein

ZFP342

Zinc finger protein 342

xv

CHAPTER ONE:
NANOG OVEREXPRESSION ALLOWS HUMAN MESENCHYMAL STEM
CELLS TO DIFFERENTIATE INTO NEURAL CELLS

Chapter Summary

Stem cell therapies have been proposed as a treatment option for
degenerative disease, like Alzheimer’s disease (AD), but the best stem cell
source and their therapeutic efficacy remain uncertain. Embryonic stem cells
(ESCs) can efficiently generate multiple cell types, but pose ethical and
clinical challenges, while the more accessible adult stem cells have a limited
developmental potential. The primary objective of this article is to show that
following over-expression of an ESC gene, nanog, adult human mesenchymal
stem cells (HMSCs) could be dedifferentiated into cells exhibiting ESC
characteristics based on morphology, immunohistochemical staining, and
gene expression. After expansion, nanog-transfected HMSCs had the
potential to be directed toward neural cell lineage under influence of
conditional media from differentiated human neural stem cells using a
membrane-separated co-culture system. Recommitted cells differentiated into
cells immunopositive for βIII-tubulin and glial fibrillary acidic protein, indicating
the presence of neurons and astrocytes, respectively. We further
demonstrated the ability of dedifferentiated HMSCs to survive, migrate, and
undergo neural differentiation in vivo in rodents. This data offers an exciting
prospect that adult cells can be modified and used to neurodegenerative
conditions.
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Introduction

Dementia is a serious medical illness that affects an estimated 24.3
million people worldwide[1] at a cost of $315.4 billion annually[2]. Severe
cognitive impairment from Alzheimer’s disease (AD) is associated with the
majority of dementia cases. While most pharmacological treatments for AD
fail to improve cognition, several lines of evidence suggest that neuroreplacement therapy may reverse cognitive impairment. Namely,
neurogenesis is associated with cognition and is congruously impaired with
aging.[3, 4] Second, neural stem/progenitor cell proliferation and
differentiation are significantly diminished in AD and Down’s syndrome
models both in vitro and in vivo.[5-8] Finally, cognitive performance improves
through increasing neurogenesis from an enriched environment[9-11],
pharmacological treatment[11, 12], or following stem cell transplantation[1216]. Although Gallagher’s group failed to show a relationship between
neurogenesis and cognition in a normal aging rodent model,[17, 18] the
collective body of evidence suggests that neurogenesis is important for
maintenance of normal brain function.
Embryonic stem cells (ESCs) have been proposed as treatment for
neurodegenerative diseases because of their pluripotency, but concerns over
ethics[19-21], immune response[22-24] and tumor formation[25-28] have
been major barriers for their clinical use. Utilization of adult stem cells could
eliminate these issues because they can be harvested from a patient and
autologously transplanted back to the patient. However, the ability of adult
2

stem cells, such as human bone marrow-derived mesenchymal stem cells
(HMSCs), to develop along multiple lineages is limited. Although studies have
claimed that HMSCs transdifferentiate into cells outside their restricted germ
layer, the transdifferentiation could have been from a very limited population
of HMSCs[29-31] or due to the low frequencies of cell fusion, which allow
MSCs to acquire characteristics of multiple cell types by fusing to somatic
cells.[32-34] Therefore, a strategy to increase the potency of adult stem cells
is requisite for their use in neurotherapy.
In a prior study, we demonstrated that HMSCs treated with
bromodeoxyuridine (BrdU) undergo neural differentiation following
transplantation in the brains of rats and improve cognitive function.[13]
However, efficiency of transdifferentiation and concerns with the use of BrdU,
which is incorporated into the DNA as a thymidine analog, led us to explore
other strategies.
One possible strategy is cell fusion that would alter the characteristics
of the adult stem cells based on the exogenous cell used for merging. This
method could change the potency of cells allowing them to develop into cells
beyond their respective lineage.[35-38] The fusion of somatic cells to ESCs
prompts expression of the embryonic stem cell gene Oct-4.[38, 39] Thus, the
expression of stem cell genes that regulate self-renewal and pluripotency may
play an integral role in reprogramming the cell lineage.
Earlier studies have indicated that the expressions of critical stem cell
genes are capable of maintaining ESCs in a pluripotent state. The
suppression of ESC differentiation has been demonstrated with the over3

expression of ESC genes including nanog[40, 41], Pem[42] and Rex1[43],
although the presence of elevated levels of Oct-4 was insufficient to guard
against ESC differentiation.[44] In this study, we tested our hypothesis that
developmental potency of MSCs can be gained by changing the gene
expression profile through the over expression of nanog, and the resulting
cells can be transdifferentiated into neural cells. This technology may allow us
to use patients’ own HMSCs to treat neurodegenerative diseases, such as
AD.

Materials and Methods

Cell Culture

Adult human bone marrow-derived HMSCs (Cambrex) were cultured in
DMEM (Invitrogen) supplemented with 1% antibiotics (Invitrogen) and 10%
FBS for improved HMSC growth (StemCell Technologies). Per Cambrex
product information, mesenchymal stem cells are harvested and cultured from
normal human bone marrow. Cell purity is far higher than cells from traditional
Dexter cultures. Cells are tested for purity by flow cytometry and for their
ability to differentiate into osteogenic, chondrogenic and adipogenic lineages.
Cells are positive for CD105, CD166, CD29, and CD44. Cells test negative for
CD14, CD34 and CD45. Media systems are available to support growth of
HMSCs, and their differentiation into adipogenic, chondrogenic, and
4

osteogenic lineages. Cells were cultured in T75 tissue culture treated flasks
(BD Biosciences) and incubated in a CO2 chamber at 37℃ with 5% CO2
(NuAire). Co-culture experiments were carried out using differentiated NSCs
in Falcon tissue culture treated 6-well plates (BD Biosciences). Prior to coculture, fetal-derived human NSCs (Cambrex) were expanded in serum-free
NSC medium of DMEM/F12 (Invitrogen) supplemented with B27 (1:50,
Invitrogen), basic Fibroblast Growth Factor (bFGF, 20 ng/ml, R&D Systems),
Epidermal Growth Factor (EGF, 20 ng/ml, R&D Systems), heparin (0.18 U/ml,
Sigma), and 1% antibiotics (Invitrogen). Cells were allowed to spontaneously
differentiate for one week in tissue culture treated 6-well plates containing
serum-free neural basal medium.
For co-culture, cell culture inserts with a semi-permeable membrane
with 0.4 μm pores (BD Biosciences) were used to separate the Nanogtransfected HMSCs from the differentiated HNSCs. This allowed for the
dynamic exchange of secreted factors and eliminated direct cell contact to
avoid possible cell fusion. Nanog- or mock-transfected HMSCs were then
transferred to co-culture to promote neural differentiation. To eliminate Nanog
expression in viral-loxP-Nanog-transduced HMSCs prior to the co-culture,
plasmids containing the Cre recombinase gene regulated by an EF1α
promoter (Addgene, plasmid 11918) were transfected into the cells using the
FuGene 6 reagent. Cells were allowed to differentiate for 10 days and then
stained for early (βIII-tubulin) and mature (MAP2) neuronal markers and
astrocytic markers, GFAP and S100.

5

Cloning of Nanog Gene

Nanog was originally cloned from male genomic DNA that was predigested with the restriction enzymes NotI, XbaI, and SpeI, then amplified by
PCR using Nanog-specific primers, (CGTTCTGCTG- GACTGAGCTGGTT,
CGGGCGGATCACAAGGTCAG). PCR conditions consisted of pre incubation
at 94℃ for three minutes, 30 cycles consisting of 94℃ for one minute, 52℃ for
30 seconds, and 72℃ for three minutes, and post dwells at 72℃ for 10
minutes. The PCR pro- duct was then placed into a mammalian expression
vector (TopoHisMax 4.1, Invitrogen) according to manufacturer’s protocol.
The cloned sequence was confirmed by DNA sequencing.

Production of Lentivirus Containing Nanog

The gene encoding for Nanog (gift from Austin Smith, MD University of
Cambridge) was amplified using the Herculase II fusion DNA polymerase
(Promega) and gene-specific primers containing a BamHI enzyme-cutting site
in the forward primer and a SalI-cutting site in the reverse primer
(ATAGGGATCCACATGAGTGTTGACCCAGCTT,
ATAGGTCGACTCACACGTCTTCAGGTTGCA). The PCR amplified Nanog
was sub-cloned into the pLox lentiviral vector (gift from Didier Trono, MD and
Patrick Salmon, MD, LVPU, Centre Médical Universitaire, Genève,
Switzerland).
6

Production of a lentiviral vector containing the Nanog sequence was
carried out using a vector containing a LoxP site. The pLoxNanog vector, the
packaging vector pCMVΔR8.91 (AddGene) encoding for regulatory proteins
Tat and Rev as well as the Gag and Pol precursors, and a vector for the
envelope protein VSV-G (Clontech) were used for viral production. The
aforementioned vectors and lentiviral vectors pLoxNanog and pLo xGFP,
combined with the packaging and envelope plasmids at a ratio of 2:1:1
(pLox:pCMVΔR8.91:pVSV-G) [45, 46], were transiently transfected into the
HEK293T/17 cell line (ATCC) using Lipofectamine (Invitrogen) at a DNA
(20µg) to Lipofectamine ratio of 1:2.5. The cell culture media was removed at
24 hours and collected every 12 hours thereafter for the next two days to
harvest the viral supernatant.

Non-viral and Viral Gene Delivery

For non-viral gene transfection, 75% confluent HMSCs were
transfected with 3μg of Nanog vector using two different reagents,
Neuroporter (Gene therapy systems) or FuGene 6 (Roche), at DNA to reagent
ratios of 1:15 and 1:3, respectively. Proliferative clusters began to emerge
after one week and grew large enough for expansion typically by three weeks.
Clustered cells that resembled Nanog-transfected HMSCs were passed by
mechanical dissociation from the feeder layer and subsequently plated with a
feeder cell layer of HMSCs.
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For lentivirus-mediated transfection, viral supernatant was transferred
to HMSC cultures for viral transduction. Delivery of Nanog was analyzed
through fluorescent microscopy for positive green fluorescent protein (GFP)
expression. Differentiation was induced through the deletion of the Nanogcontaining proviral sequence with a vector encoding for Cre recombinase
(Addgene pBS513)[47-49]. The Cre vector, which contains an EF1α promoter,
was delivered to the cells through chemical transfection. Following Cretransfection, cells were used for neural differentiation or gene expression
analysis at 72 hours post-transfection. All recombinant DNA research was
performed in accordance with NIH guidelines.

Gene Expression Analysis

RNA extraction was performed using TRIzol (Invitrogen) according to
manufacturer’s instructions. Media was removed from cultured cells and
incubated with 1ml of TRIzol for five minutes at room temperature. The TRIzol
solution was phase-separated by an addition of chloroform, thoroughly mixed,
and centrifuged at 11,500g for 15 minutes. The RNA was precipitated from
the top aqueous phase by isopropanol, centrifuged at 11,500g for 10 minutes,
and the RNA pellet was washed with 75% ethanol. The RNA-ethanol solution
was centrifuged for five minutes at 7,400g, the supernatant removed, and the
pellet was re-suspended in molecular biology grade water. RNA concentration
were measured based on absorption and converted to cDNA for PCR
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analysis. Reverse transcription was performed using an iScript cDNA
synthesis kit (Bio-Rad).
Primers used for RT-PCR were GAPDH
(AGCCACATCGCTCAGACACC, GTACTCAGCGGCCAGCATCG), β-actin
(TCCTGAGCGCAAGTACTCC, AAGCATTTGCGGTGGACGA), Nanog
(ACAACTGGCCGAAGAATAGC, AGTGTTCCAGGAGTGGTTGC), Oct-4
(CTTGCTGCAGAAGTGGGTGGAGGAA, CTGCAGTGTGGGTTTCGGGCA),
TERF1 (GCAACAGCGCAGAGGCTATTATT,
AGGGCTGATTCCAAGGGTGTAA), Sox-2 (ATGCACCGCTACGACGTGA,
CTTTTGCACCCCTCCCATTT), ZFP342 (GAAGGCATCACCCAAAAAGA,
GCGGTTGAGCTTACTGCTCT), TERT (CGGAAGAGTGTCTGGAGCAA,
GGATGAAGCGGAGTCTGGA), and eGFP (CCTGAAGTTCATCTGCACCA,
GGTCTTGTAGTTGCCGTCGT).
Real-time two-step RT-PCR was performed using a SYBR green PCR
mix (Bio Rad), carried out in a My-IQ iCycler (Bio Rad) and then analyzed by
the ΔCt method as previously described [50, 51].

Stem Cell Transplantation

Two different transplantation studies were performed with C57/Black
mice at four months of age in accordance with approved protocols from the
University of Central Florida’s Institutional Animal Care and Use Committee.
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The animals were fixed in a stereotaxic apparatus and approximately
1x10^5 cells in 10μl of phosphate-buffered saline (PBS) were slowly injected
into the right lateral ventricle (coordinates: AP -1.4, ML 1.8, DV 3.8).
Experiments were carried out independently using HMSCs dedifferentiated
through non-viral transfection or lentiviral transduction.

Stem Cell Transplantation

Two different transplantation studies were performed with either six
eight-month Fisher 344 rats for non-viral dedifferentiated cells or C57/Black
mice for virally-transduced cells for transplantation in accordance with
approved protocols from the University of Central Florida’s Institutional Animal
Care and Use Committee. Prior to transplantation, animals were anesthetized
with intraperitoneal injections of a solution mixture of ketamine hydrochloride
and xylazine (X-Ject) (1:1 ratio). Adequate sedation was determined by a lack
of palpebral and tail-pinch reflexes.
Once properly sedated, animals were set atop a platform of appropriate
height and secured within a stereotaxic apparatus using the nose clamp and
ear bars. The heads of the animals were shaved and an anterior to posterior
incision was made with a surgical scalpel to reveal the skull. Using bregma as
a reference, the location of the right lateral ventricle was located using a brain
atlas, and a needle hole was carefully drilled through the skull but not into the
brain. Approximately 1x10^5 cells in 10µl of phosphate-buffered saline (PBS)
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were slowly injected into the right lateral ventricle (coordinates: AP -1.4, ML
1.8, DV 3.8). Cells in solution were kept on ice and adequately re-suspended
to avoid cell aggregation. Experiments were carried out independently using
HMSCs dedifferentiated through non-viral transfection or lentiviral
transduction. Following injection, residual blood was gently cleaned with
sterile cotton swabs and the incision closed using surgical clamps. Animals
were post-surgically monitored for signs of bleeding, infection, and behavioral
changes.

Brain Sample Preparation

Animals were deeply anesthetized and perfused using a 10% sucrose
solution followed by fixation with a 4% paraformaldehyde PBS (pH 7.2).
Following fixation, brains were removed and placed inside a 20% sucrose/4%
paraformaldehyde solution and left overnight at 4℃. When the brain settled to
the bottom of the container, it was froze in isopentane pre-cooled by
submerging the beaker into liquid nitrogen. The brains were mounted using a
cryomedium, sliced into 20µm sections using a cryostat at –20℃ and
collected in PBS and stored at 4℃ until antibody staining.
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Immunocytochemistry and Immunohistochemistry

Cultured cells were washed with PBS then fixed with a 4% buffered
paraformaldehyde (Sigma) solution overnight at 4℃. Following fixation, cells
were washed with PBS (Sigma) then permeabilized with PBS-Tween (Sigma)
containing 0.1% Triton-X (Fisher Scientific) for one hour at room temperature.
Brain sections were washed with PBS then permeabilized by incubation in
PBS-Tween with 0.1% Triton-X at room temperature for one hour. The
samples were then incubated for one hour at room temperature in a blocking
solution of PBS-Tween with 3% donkey se-rum (Jackson ImmunoResearch).
Primary antibodies TRA-1-60 (MAB4360), SSEA-3 (mab4303), Sox-2
(AB5603), MAP2 (AB5622), and Oct-4 (mab4305) all from Chemicon, Nanog
(AF1997, R&D Systems), βIII-tubulin (T8660, Sigma), S100 (S2644, Sigma),
and GFAP (G9269, Sigma) were added to blocking solution and incubated
overnight at 4℃. The next day, samples were washed with PBS and
incubated in the dark with FITC- or TRITC-conjugated secondary antibodies
at room temperature. Samples were washed with PBS, cover-slipped with
water-based mounting solution containing DAPI (Vector Laboratories), and
sealed using clear nail polish.
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Results

Cloning of nanog: Sequence analysis showed over 99% sequence
identity with nanog but did not contain introns, suggesting that it may be
nanog pseudogene 8 (NANOGP8),[52] one of twelve nanog variants.[52-56]
The high homology and intact coding region suggests that the cloned
sequence should be indistinguishable from nanog and the translated product
virtually identical to the actual nanog protein, with the exception of
substitutions occurring in residues 16 and 253, changing alanine and
glutamine for glutamate and histidine, respectively. The cloned gene
sequence can be segmented into seven distinct regions: the 5’ untranslated
region (UTR), N-terminal domain, homeodomain, C1 domain, Cw domain, C2
domain, and the 3’ UTR. The 5’ region contains binding sites for embryonic
stem cell genes Oct-4 and Sox-2, which are part of a transcriptional regulatory
loop.[57-60] The 5’ region also contains a p53-binding site within the nanog
promoter region that facilitates ESC differentiation[61] and is possibly
responsible for the shift in replication timing observed with neural
differentiation.[62] The N-terminal region of nanog has transcriptional
activity[63] and encodes for a sequence containing a SMAD-binding
domain.[54, 64] The homeodomain portion is similar to the NK-2 and ANTP
family of homeodomain transcription factors, but comparing 120 different
homeodomain proteins using BLOcks SUbstitution Matrix (BLOSUM) and
Point Accepted Mutation (PAM) matrices suggests that nanog represents a
distinct protein family divergent from both the NK-2 and distal-less gene family
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(data not shown). The C-terminal domain contains no apparent transactivation
motifs, but has greater transactivation activity compared to the N-terminal and
homeodomain.[63, 65]
The C-terminal domain can be subdivided into three regions: the
portion immediately following the homeodomain region (C1), the subregion
containing a unique repeated motif of tryptophan flanked with four polaruncharged amino acids (Cw), and a more distal sequence (C2). Cloning of
nanog inside the pLox lentiviral vector was successful and DNA sequencing
confirmed a match for the actual nanog gene. The nanog sequence was
properly inserted into the vector containing LoxP sequence within the long
tandem repeat, allowing for efficient proviral deletion following delivery of Cre
recombinase.[55, 56]
Transfection of nanog: In the current study, human bone marrow
HMSCs were cultured and grown to 75% confluence and treated with a
plasmid containing nanog or served as mock-transfected control. Following
optimization, we achieved transfection rates of less than 5% using non-viral
transfection. Nanog transfection altered the morphology of cells, producing
smaller proliferative cells that themselves formed clusters (Figure 1, A).
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Figure 1: (a) HMSCs over-expressing Nanog displayed ESC-like (v-viii) or EBlike morphology (ix-xii). Morphological changes seen at three weeks (i,v,ix),
two (ii,vi,x), three (iii,vii,xi), and six months (iv,viii,xii) post-transfection. (b)
HMSCs nine days post-transduction with Nanog lenti-virus (ii). Three weeks
following non-viral Nanog transfection (iii) and three days later (iv). Untreated
HMSCs showed as a control (i).
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Two basic cell types were observed; namely, the proliferative clusters
tended to form either an adherent mass of cells that were ESC-like or more
spherical, non-adherent/loosely adherent clumps somewhat resembling
embryoid bodies (EB-like). The EB-like cells originated as small, scattered
clumps, but formed larger aggregates within weeks. These larger clusters
were mainly the result of clump aggregation rather than cell proliferation.
Transfection with the neuroporter reagent appeared to have more
toxicity and was more likely to produce EB-like cells, therefore FuGene 6 was
the preferred transfection reagent. Cells that displayed the flattened, ESC-like
morphology were detected as early as one week, but were usually distinct at
two to three weeks. The number of colonies produced did not appear to
directly correspond to transfection rates. Following one week, one or two
colonies could be observed in the wells. No colonies were able to expand
without a feeder layer, and only a few colonies were able to expand into larger
colonies of thousands of cells for subsequent passaging.
Moreover, the colonies that did form and display ESC-like morphology
were only found within the nanog-transfected cell cultures. Both of the
previously defined cell types either adhered and differentiated or underwent
cell death when transferred to separate culturing flasks with no feeder layer
(data not shown). The inability of isolated colonies to continually proliferate on
their own indicates that the majority of non-transfected HMSCs served as a
feeder layer, helping provide growth factors and aid in cell survival. ESC-like
colonies were less homologous and displayed greater propensity for
differentiation than has been reported with ESCs (Figure 1A).
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There was little difference between ESC-like cells and ESCs for up to
two months in culture, and while they were able to proliferate, they did not
appear to grow past 1000µm. However, by three months, gradual changes
became evident as heterogeneity within the structures became more
apparent. It is uncertain whether this phenomenon is the result of cells
undergoing differentiation, reaching a proliferative limit, or the result of
changes in the underlying feeder layer of un-transfected HMSCs. Control
HMSCs showed changes in morphology at three months in culture, and by
three months displayed little or no proliferation.
Beyond three months, the number of nanog-transfected ESC-like cells
diminished, and mock-transfected HMSCs showed age-related alterations.
HMSCs could be cultured for longer periods of time through continuous
passages, but late-passaged HMSCs displayed changes in morphology,
including increased cell size, larger cytoplasm, and no detectable proliferation.
Following one year of culturing and expansion, HMSCs failed to survive and
few ESC-like cells remained.
Cells co-transduced with nanog and GFP lentiviruses showed
prominent cluster formation (Figure 1B). Colonies formed by transduction with
nanog were easier to maintain and grew much larger than HMSCs chemically
transfected with nanog. Colonies produced through chemical transfection
were difficult to maintain as the colonies tended to disperse (Figure 1B).
Gene expression and immnohistochemistry of nanog-transfected
HMSCs: Exploring biochemical changes following nanog transfection, we
performed RT-PCR for nanog and Oct-4 to compare with mock-transfected
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HMSCs, as well as immunostaining for known embryonic stem cell markers.
Expression levels of nanog and Oct-4 were absent or low in two different
batches of mock-transfected HMSCs (Figure 2).

Figure 2: (a) RT-PCR shows little or no expression of Nanog and Oct-4 in
mock-transfected HMSCs but up-regulation of both at two, five, and eleven
months following Nanog transfection up to 11 month in a culture. GAPDH was
a control. (b) qRT-PCR of Nanog lentiviral-transduced cells. Up-regulation of
multiple ESC genes after Nanog transfection (grey) were observed and these
genes were down-regulated after (black) delivery of Cre recombinase vectors
to remove Nanog expression.
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This illustrates the heterogeneity of HMSCs in culture and is consistent
with the data showing a subpopulation of pluripotent HMSCs.[29-31, 66, 67]
Following nanog transfection, expression of both nanog and Oct-4 were highly
elevated at two, five, and eleven months. It was unexpected that either nanog
or Oct-4 would be expressed following long-term expansion since the few
remaining cell clusters did not appear to proliferate at one year. Interestingly,
levels of Oct-4 did not directly correlate with expression of nanog, which is
consistent with findings that Oct-4 is not directly controlled by nanog.[57, 58,
68]
Quantitative gene expression analysis was difficult given the
heterogeneous population and relatively low frequency of nanog-transfected
cells. We therefore attempted to select out nanog-dedifferentiated cells using
a lentiviral system and green fluorescent protein. Using lentiviruses to deliver
nanog and GFP, we created dedifferentiated cells that were more
homogenous, highly proliferative, and easily expandable. In fact, the cells
were able to grow with or without feeder cells for over 40 passages.
Quantitative real-time PCR was performed on lentiviral-transduced
cells and showed a dramatic increase in most of the ESC genes tested. We
were able to detect low levels of both nanog and Oct-4 in two of three HMSC
batches tested, but telomerase expression was absent. Following forced
expression of nanog, we measured dramatic increases in nanog, Sox-2, zincfinger protein 342, TERF1 and telomerase. Given the lack of telomerase
expression, we assigned the lowest value for detection in order to perform an
analysis that does not allow for “zero” expression. We observed only a
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modest, yet statistically significant, increase in levels of Oct-4 to four times the
normal level (Figure 2). The measured changes, particularly the sudden
expression of telomerase and increase in TERF1, demonstrate fundamental
changes in the HMSCs following delivery of nanog. Previous work has
revealed that human HMSCs fail to express telomerase and have a unique
telomerase biology compared to other stem cells,[69, 70] so the link between
nanog and telomerase is an exciting area that warrants exploration.
Removing nanog and GFP using a vector encoding for the Cre
recombinase enzyme should reverse gene expression changes in the viraltransduced cells. Recombination and gene excision was successful, as most
viral-transduced cells were negative for GFP post-Cre transfection, allowing
for neural differentiation. Additionally, real-time PCR reveals an 89% decrease
in GFP expression in viral-transduced cells 72 hours following delivery of Cre
(data not shown). We compared changes in gene expression changes in Cretransfected, virally-dedifferentiated cells and found reduction in most stem
cells genes. Nanog, Oct4 and TERF1 showed a 70% to 80% decrease in
expression, while Sox-2 and telomerase showed decreases of approximately
98% each (Figure 2b).
Immunohistochemical staining was performed using antibodies against
the ESC markers nanog, Oct-4, stage-specific embryonic antigen-3 (SSEA3),
and keratan sulphate-associated antigen TRA1-60. If nanog dedifferentiates
HMSCs, transfected cells should stain positive for ESC markers. The vast
majority of untreated cells failed to stain for any ESC markers, but a small
population (approximately 1%) of cells, did show positive staining for
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transcription factors Oct-4 and nanog, while faint staining for surface markers
was seen in about 5% of cells (Figure 3). Alternatively, nanog-transfected
cells did display positive staining for the ESC transcription factors nanog and
Oct-4 within the proliferative cell clusters, although not in the surrounding
feeder layer of HMSCs. Nanog-transfected cell clusters also showed positive
expression of ESC surface markers SSEA3 and TRA1-60 (Figure 3).

Figure 3: Immunocytochemistry of Nanog transfected HMSC colonies showed
strong immunoreaction for ES cell markers after15 weeks in a culture (v-viii)
while there is no expres- sion of ES cell markers in mock-transfected HMSCs
(i-iv). The cells were immunostained for Nanog (i, v), Oct-4 (ii, vi), SSEA-3 (iii,
vii), and TRA-1-60 (iv, vii).

This staining pattern was more apparent with the use of the GFP and
nanog lentiviral-transduced cells. Following transduction with nanog and GFP,
large ESC-like colonies began to form. GFP expression appeared localized to
ESC-like colonies and showed positive staining for manog and Sox-2, unlike
non-treated HMSCs (Figure 3B). Taken together, it appears that forced
expression of nanog results in the dedifferentiation of HMSCs and induces the
expression of ESC markers.
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We next tested the ability of nanog-transfected cells to undergo neural
differentiation using a previously established co-culture system.
Dedifferentiated cells were placed in co-culture consisting of a feeder cell
layer separated by a semi-permeable membrane to eliminate direct cell
contact. The feeder cells used were neurons and glial cells derived from
human neural stem cells, and were grown as neural spheres and cultured in
serum-free basal media. This system allows for the exchange of growth
factors and eliminates the concern over cell fusion since it prevented direct
cell contact between the HMSCs and underlying feeder cells. Cell clusters
adhered to the membrane surface and differentiation occurred as cells
radiated outwards. Control HMSCs adhered to the membrane surface but
failed to differentiate into neurons and astrocytes. The differentiation pattern
was tested by immunostaining against βIII-tubulin and GFAP, neuronal and
astrocytic markers, respectively (Figure 4).
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Figure 4: With mock-transfected HMSCs showed no ESC- like colony
formation (i,v) nor GFP expressions (ii,vi) and immunoreactivities for Nanog
(iii) and Sox-2 (vii) are not detected. Lentiviral transduction with Nanog and
GFP in- duced colony formation (ix, xiii) and GFP expression (x, xiv), and
positive for Nanog (xi) and Sox-2 (xv) immunore- activities. DAPI is used
counter stain of nuclei (iv, viii, xii, xvi).
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The un-transfected HMSCs did not show positive staining for the
neuronal marker βIII-tubulin, but approximately two percent of the cells did
show weak expression of GFAP. This may represent a subpopulation of
pluripotent HMSCs[30, 66] that is capable of differentiating into astrocytes.
Modified cells formed spherical clusters with a similar appearance to
differentiated neural stem cells, forming a web-like network of neurons and
astrocytes that stained positive for both βIII-tubulin and GFAP (Figure 5).
However, βIII-tubulin and GFAP are early lineage commitment markers, so we
examined the expression of MAP2 and S100 to determine if these mature
neuronal and astrocytic markers would be expressed following neural
differentiation to our dedifferentiated cells. Induction of differentiation in the
viral-transduced cells was achieved by first transfecting the cells with a vector
encoding for Cre recombinase, then placing the cells in conditioned media for
neural differentiation. Cre-transfection was successful, as evident by the
majority of cells now being GFP negative. We found that some cells did show
positive staining for both markers, and most cells were negative for GFP
(Figure 6).
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Figure 5: After co-culture with differentiated human neural stem cells, naive
HMSCs showed few GFAP (red) but no βIII-tubulin (green) immunoreactivites
(i). While Nanog- transfected HMSCs forming clusters of cells co-cultured with
differentiated human neural stem cells attached to the culture insert
membrane and migrated outward. They were positive for GFAP (red) and βIIItubulin (green) immunoreactivites indicating neural differentiation of the cells,
(low magnification in ii, high magnification in iii). Differentiated Nanogtransfected HMSCs are also stained positive for MAP2 (green) and S100 (red)
at two weeks, indicating differentiation into mature neurons and astrocytes,
respectively.
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Figure 6: After transplantation into mice, Nanog-GFP transfected HMSCs
HMSCs are capable of migration into hippocampus dentate gyrus (i).
Immunostaining specific to human βIII-tubulin (green) and GFAP (red)
indicated that the transplanted Nanog-transfected HMSCs after Cre
recombinase treatment differentiated into neurons and astrocytes in the
dentate gyrus (ii, iii) and CA1 regions (iv) of the hippocampus, respectively.
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Immunohistochemical staining shows expression of early neuronal
(βIII-tubulin) and astrocytic (GFAP) markers at three days in neural
differentiation culture. Cells were cultured for two weeks and stained for
mature neural markers. Cells stained positive for MAP2 and S100, indicating
the cells were able to express mature neuronal and astrocytic makers,
respectively.
Transplantation results: We tested the cell fate and migration of nonviral and lentiviral dedifferentiated HMSCs in vivo three weeks posttransplantation. Following sacrifice, the brains were sectioned and examined.
None of the animals displayed evidence of tumors, but a separate cluster of
cells was observed in one region of brain sectioning, presumed to be from the
original transplantation. Immunohistochemical staining for human βIII-tubulin
and GFAP did reveal evidence of both in vivo neuronal and glial
differentiation. Moreover, the presence of transplanted cells, marked by the
expression of human neural markers or GFP in the Cornu Ammonis fields of
the hippocampus proper and dentate gyrus regions, is encouraging given the
role of these structures in learning and memory (Figure 6).
The high frequency of transdifferentiation demonstrates a new
technology that neither relies on cell fusion nor the enrichment of low
frequency subpopulations of cells that can be applied for neuroreplacement
therapies.
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Discussion

This study demonstrates a novel method of dedifferentiating adult stem
cells by over-expressing genes regulating pluripotency, with the end goal of
facilitating neural transdifferentiation of HMSCs, which may allow us to
perform autologous cell therapies for individuals with AD and other
neurodegenerative diseases. Nanog transfection of HMSCs produced
proliferative cells with morphological and gene expression similarities to
ESCs.
We previously demonstrated that treatment with the nucleotide
derivative BrdU allows for transdifferentiation,[13] and other groups have
demonstrated that fusion of stem cells and somatic cells can alter cell
properties.[34, 37, 38, 71] In the current study, we show that HMSCs can be
dedifferentiated by gene delivery of only nanog, although other factors already
present in the cells may contribute to forming ESC-like cells. Recently,
delivery of four factors induced pluripotency in mouse fibroblasts. Their use of
transcription factors Oct-4, Sox-2, and KLF4 along with the oncogene cMyc
was sufficient to induce pluripotent transformation.[72-75] These results have
been independently achieved by different labs using human cells with the
same set of genes[76-78] or with a combination of nanog, Oct-4, Sox-2, and
Lin28.[79]
We found levels of Oct-4, Sox-2 and other genes related to
pluripotency and self-renewal were significantly increased after nanog overexpression. Previous reports failed to show formation of ESC-like cells using
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any single ESC gene when delivered to stem cells or fibroblasts,[80, 81] nor
by combining Oct-4, Sox-2, Klf4 and Myc in adult HMSCs.[77] The use of
additional vectors encoding for the simian virus large T antigen (SV40T) and
the catalytic subunit for telomerase (hTERT) were able to produce a few
colonies but still showed cellular loss with expansion.[77]
The difficulty in converting HMSCs is likely the result of a number of
critical factors. First, mesenchymal stem cells have a limited capacity for
expansion and vary in their ability to proliferate and differentiate, qualities that
decrease with age and vary among sources. They are sensitive to culturing
conditions, particularly plating density, supplements and serum quality.[82-85]
Gene delivery experiments are also challenging in these cell types given their
difficulty to transfect, death from toxicity,[86-89] their propensity to undergo
senescence after several passages,[69, 90, 91] or toxicity associated with
viral transductions.[89, 92] Additionally, heterogenetity within HMSCs and
variation between cultures may account for conflicting results. Research with
HMSCs has often produced conflicting results, especially when examining
proliferation and stem cell markers.
Previous studies are inconsistent regarding the expression of
embryonic stem cell transcription factors Nanog, Oct-4, and Sox-2 in adult
stem cells. Oct-4 is present at low levels in HMSC in vitro cultures or can be
induced in a subtype of cells using various culture conditions.[30, 84, 93, 94]
However, low levels sox2 and nanog are detected in some, but not all
HMSCs.[67, 84, 95-97] This inconsistency extends to telomerase activity and
the ability to immortalize HMSCs.
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Similar to genes associated with pluripotency, telomerase activity has
been detected in MSCs by some groups,[98, 99] but not by others.[69, 70,
100-102] Conflicting results are also observed when groups have attempted
to immortalize HMSCs through viral delivery of telomerase. Overexpression of
telomerase appears to overcome early senescence and generate
immortalized cell lines[103-106] while other groups report hTERT alone is
insufficient.[100, 101] Alternatively, only a subpopulation of HMSCs may be
dedifferentiated by nanog. Presumably cells that endogenously express other
necessary stem cell genes would undergo dedifferentiation. This hypothesis is
supported by the ability to convert neural stem cells, which already express
many stem cell factors including Sox2 and cMyc, to pluripotent cells through
forced expression of two factors, Oct-4 and Klf-4,[107] or just Oct-4
alone.[108-110]
In addition to the presence of critical stem cell genes, the level of
expression is likely to be imperative in determining cell conversion. Since the
combination of Oct-4 and Sox-2, which up-regulates nanog, failed to convert
the adult cells to ESC-like cells,[59, 60] high levels of nanog may be the
critical factor. Other research found that selection of the cells expressing high
levels of nanog after transfection with combination of Oct-4 and Sox-2 has
yielded ESC-like colonies.[74]
We observed that the number of ESC-like cell colonies that formed
after nanog transfection did not directly correspond to the number of cells
receiving the gene. This may be due to the heterogenous population of
HMSCs, which varyingly express other factors required to produce ESC-like
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cells. Passage number of HMSCs may contribute to variability in results,
because changes to HMSCs’ ability to differentiate and rate of proliferation
are evident by passage six.[90] Continuous passage of cells produces
alterations and cell senescence, the proliferative limit of which is commonly
referred to as Hayflick’s limit.[90, 91]
Cells receiving a non-viral transfection of nanog tended to lose
proliferative capability while lentiviral-transfected nanog cells can be
maintained over forty passages. HMSCs show extremely low rates of stable
transfection using non-viral tranfection.[87] Thus, differences between cells
receiving nanog through chemical transfection compared to those receiving it
through viral delivery might explain the lack of stable expression of nanog in
the non-viral transfected cells. However, sustained nanog expression alone
will unlikely induce embryonic stem cell properties in most HMSCs, but will
increase their rate of proliferation.
This result, and experiments that demonstrate Oct-4 functions in a
similar manner in both HMSCs and ESCs, suggests both cell types share
similar regulatory mechanisms. Additionally, embryonic stem cells that have
been committed to a mesoderm lineage can be dedifferentiated by forced
expression of nanog. We maintain that nanog acts synergistically with other
stem cell factors to facilitate dedifferentiation. This work demonstrates the
ability of forced expression of nanog to interact with endogenous factors to
induce dedifferentiation and expand developmental potential of cells.
This method may be advantageous in developing neural cells without
the generation of tetraploid hybrids or ESCs. The ability to generate human
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neural cells from adult stem cells allow for the advancement of replacement
therapies for neurodegenerative diseases. Still, consideration must be given
to how transplanted cells behave under AD-pathological conditions. We
observed both glial and neuronal differentiation in aged wild-type mice, but it
is uncertain whether this will translate to efficient neuronal differentiation in a
disease model.[111, 112] Our previous work has suggested that stem cells
will have impaired neuronal differentiation following transplantation into an AD
model animal, which shows elevated levels of amyloid β precursor protein
(AβPP).[113]
A closer examination in vitro demonstrated the dose-related effects of
AβPP in regulating glial differentiation.[114] Recently, our lab has also
demonstrated that neuronal differentiation can be achieved by lowering levels
of AβPP in the brain using (+)-phenserine.[115] Technology such as this
allows both for adult cells to be used in cell replacement therapies for a
variety of diseases and also for the ability to create disease-specific cell lines
from patients that can be used for research and development of personalized
drugs. Although a cure for AD may not be immediate, our results may move
us closer toward that goal.
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CHAPTER TWO:
EMBRYONIC STEM CELL MARKERS DISTINGUISH CANCER STEM
CELLS FROM NORMAL HUMAN NEURONAL STEM CELL POPULATIONS
IN MALIGNANT GLIOMA PATIENTS

Rationale

The signalling pathways that regulate stem cell self-renewal and
pluripotency are likely to have significant implications to cancer research for
several reasons. Transplantation of embryonic stem cells form taratomas
when transplanted but differentiated cells do not. Induced-pluripotent cells
also have the capacity for tumorigenic transformation and forced expression
of the gene c-Myc, a gene critical for stem cell proliferation, facilitates
transformation of astrocytes to generate tumors with an undifferentiated
phenotype.[116] Our previous study has demonstrated the critical role of
nanog to expand the developmental potential of human mesenchymal stem
cells to pluripotent cells capable of neural differentiation. In this study, we
examine the role of embryonic stem cell genes in tumor-derived stem cells
and posit that their differential expression in cancer stem cells make them
attractive diagnostic and therapeutic markers.

Chapter Summary

Glioblastoma multiforme tumors contain a sub-population of cancer
stem cells that contribute to malignancy and resistance to therapy. Previous
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studies have characterized these cells based on their similarity to adult neural
stem cells and their expression of CD133. In this study, we separated cancer
stem cells from non-pluripotent cells comprising the bulk of the tumor based
on their respective physical growth properties using both serum and serum free cell culture media. We successfully generated cancer stem cells from
multiple tumor masses as well as from the surgical aspirate. Cancer stem
cells were able to proliferate as non-adherent spheroids and differentiated
along neuronal and glial lineages following culture in serum -supplemented
media. Compared to adherent cancer cells and human fetal neural stem cells
served as control, tumor spheroids showed increased rates of proliferation, as
measured by BrdU incorporation, and greater resistance to differentiation,
respectively. Further characterization of these cells was carried out using
immunohistochemistry and real-time PCR to reveal previously undefined
molecular markers enriched in cancer stem cells that are absent in both cells
comprising the bulk of the tumor as well as in normal neural stem cells. These
same markers are down-regulated following differentiation and may serve as
important diagnostic and prognostic factors. Moreover, the presence of these
unique markers may potentially become targets for future directed therapies.

Introduction

Glioblastoma Multiforme (GBM) is the most common and the most
aggressive type of brain tumor, responsible for 18.5% of all primary CNS
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tumors. Treatment of these tumors remains a difficult clinical challenge and
requires a multimodal approach.[117] Despite obvious benefits, surgery alone
or in combination with radiation therapy does not provide prolonged
remissions, yielding median survivals of 20 and 36 weeks, respectively, for
GBM patients.[118-121] Median survival times may be increased to up to
nearly 15 months if over 98% of the tumor is removed[122] or if chemotherapy
is integrated with surgery and radiation[123, 124]. Standard chemotherapy
plus fractionated radiation therapy and surgery yields a median survival
between 50-60 weeks.[123, 124] Unfortunately, there has been little
improvement in survival relative to the original documented average span of
44-52 weeks over 80 years ago[125]. The presence of a blood brain
barrier[126, 127] and the remarkable degree of molecular heterogeneity within
malignant glial cells[128-130] limits the therapeutic effect of chemotherapy
and makes patient prognosis poor and recurrence rates reach close to 100%.
The heterogeneity of these GBM tumors, and particularly the presence
of a subpopulation of cancer stem cells (CSCs) within them, is believed to be
critical to the tumorigenic process.[131-136] Previous studies have suggested
that these CSC cells, identified as being positive for the surface marker
CD133, within GBM tumors are able to give rise to new tumors following
transplantation into nude mice.[131, 134-137] Interestingly, transplantation of
CD133 negative cancer cells does not appear to form tumors upon
transplantation. CD133 positive cancer stem cells have been compared to
human neural stem cells both on growth properties and gene expression.[131,
134, 135] However, many of these comparative studies have been carried out
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using fetal neural stem cells rather than endogenous adult neural stem
cells.[138] All studies that cite CD133 positivity to be an adult neural stem cell
marker reference research on fetal or embryonic stem cell-derived neural
stem cells.[139-142] This distinction may be important because non-fetal adult
neural stem cells, at least in the subventricular zone, do not express CD133
and have not been as well characterized.[143]
Previous comparative studies of malignant glioma tumor cell
heterogeneity fail to provide valuable information as to the similarity of cancer
stem cells to adult neural stem cells. Many studies have cited CD133 positivity
to be a CSC cell marker even though CD133 positivity has also been
established as a marker for normal neural stem cells (NSCs).[137, 138, 140,
141] Thus, the use of CD133 as a surrogate marker to identify tumor stem
cells within a GBM may not be clinically useful as glioblastomas contain both
differentiated cancer cells and cancer stem cells in addition to normal adult
neural stem cells that migrate into the tumor.[144-146] Both NSCs and glial
progenitor cells have been found throughout the healthy normal adult
brain.[147-154] Neural stem cells travel with tumor cells migrating through the
parenchyma of the CNS.[144] In fact, NSCs appear in the area adjacent to
glioma implants five days after injection in mice.[146] This migratory
phenomenon, which is also observed in brain injury[155], has been proposed
as a means of anti-cancer gene delivery.[156, 157] If stem cells are to be a
viable vehicle for tumor therapies, then more detailed identification is needed
to prevent the accidental implantation of cancer stem cells. Thus, identifying a
specific CSC marker to distinguish neoplastic stem cells from non-cancerous
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NSCs is crucial for not only understanding the biology of tumor stem cells but
also development of effective therapies for GBM.
The ability of CSCs to undergo tumorigenesis, combined with their
resistance to chemo- and radiation- therapies,[158-160] is of particular clinical
importance given the propensity of gliomas to reemerge following surgery and
therapy. As a result, CSC cells may represent a primary therapeutic target in
order to achieve complete eradication of the tumor. Although CD133 positive
CSCs have been compared to human NSCs both on growth properties and
gene expression[131, 134, 135], definitive CSC-specific markers, which
relates to tumor stem cell biology have not been found. To help address this
problem, this study aimed to characterize different cell populations based on
growth properties and to show a distinct population of cells with cancer stem
cell properties based on specific cell marker expression patterns.

Materials and Methods

Cell Culture and Isolation

Human glioblastoma tumor masses were removed from patients
undergoing craniotomy for primary resection of newly diagnosed tumor
identified by magnetic resonance imaging (MRI). All patients provided IRB
approved informed consent for the study pre-operatively. Surgically removed
tumor specimens were washed, minced, dissociated, and then placed, within
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an hour of surgery, inside a 75cm2 flask containing re-suspension medium of
DMEM/ F12 supplemented with 10% fetal bovine serum. Following an initial
expansion in a monolayer, the tumor cells were switched to a defined serum free NSC media consisting of DMEM/F12 supplemented with 20ng/ml of basic
fibroblast growth factor (FGF-2) and 20ng/ml of epidermal growth factor (EGF)
to generate neural sphere formation at different time points. Specifically, cells
were placed directly in neural stem cell media or switched at 24, 48, or 72
hours. This culturing system generated cells with two distinct growth
properties, adherent cells and floating sphere-forming cells. Adherent cells are
likely differentiated tumor cells with limited proliferative potential. Floating
neural spheres contain multipotent stem cells. Cells were analyzed using
quantitative real-time PCR for expression of embryonic stem cell genes, stem
cell transcription factors, and telomerase. Additional characterization included
differentiation in media without growth factors such as FGF and EGF and
supplemented with fetal bovine serum and immunohistochemical analysis for
multiple protein markers.

RNA Isolation and Quantitative Real-Time PCR

Cell culture media was removed from cells and total RNA was
extracted from cells using Trizol Reagent (Invitrogen) in accordance with the
manufacturer’s protocol. Briefly, cells were spun down in a centrifuge tube at
low speed to pellet. Media was removed and 1ml of Trizol was added to the
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cells and incubated at room temperature for five minutes. After five minutes,
0.2 ml of chloroform per 1ml of Trizol was added to the tubes. The tubes were
shaken vigorously for 15 seconds and incubated at room temperature for two
minutes. Tubes were then centrifuged at 12,000 x g for 15 minutes at 4˚C.
Next, the aqueous phase of the samples was removed and transferred into a
fresh tube. To precipitate the RNA, 0.5 ml of isopropyl alcohol was added to
each tube and the tube was lightly mixed back and forth for 15 seconds.
Samples were then incubated at room temperature for 10 minutes and
centrifuged at 12,000 x g for 10 minutes at 4˚C. The supernatant was
removes and the RNA pellet was washed once with 1 ml of 75% ethanol per 1
ml of Trizol. Samples were mixed by vortexing and centrifuged at 7,500 x g for
five minutes at 4˚C. The supernatant was carefully removed and the RNA
pellet was air dried for approximately 10 minutes. The RNA pellet was then
resuspended in 100 µl of microbiology grade water and tubes were incubated
for 10 minutes at 55˚C. RNA concentration was measured using
spectrophotometry. A 1:50 dilution was created using water and absorption
readings were taken at 260nm (correlating to RNA concentrations) and
280nm (the ratio of A260/A280 relating to RNA purity). The
spectrophotometer was calibrated using cuvettes containing only water.
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cDNA synthesis

RNA was reverse transcribed for RT-PCR using iScript cDNA
Synthesis Kit (Biorad) to form cDNA. The cDNA reaction took place under the
following conditions: 25˚C for 5 minutes, 42˚C for 30 minutes, 85˚C for 5
minutes, and held at 4˚C.

Real-Time PCR

Gene expression was measured by quantitative real-time PCR (qRTPCR) using gene specific primers. Real-Time PCR was performed using the
MyiQ SuperCycler Real Time PCR Detector System (Biorad) using iQ
Supermix with SYBR Green (Biorad) for detection. Each reaction tube
contained, 12.5 µl of SYBR Green, 8 µl of microbiology grade water, 1 µl of
forward primer, 1µl of reverse primer, and 2.5 µl of cDNA, for a total reaction
volume of 25 µL. Primers used for real time PCR were: TERT, F 5’CGGAAGAGTGTCTGGAGCAA-3’, R 5’-GGATGAAGCGGAGTCTGGA-3’;
CD133, F 5’-CAGAGTACAACGCCAAACCA-3’, R 5’AAATCACGATGAGGGTCAGC-3’,
Nanog F 5’-ACAACTGGCCGAAGAATAGC-3’, RAGTGTTCCAGGAGTGGTTGC-3’; Sox2, F 5’CGGTACCCGGGGATCCCCGCATGTACAACATGATGG-3’, R 5’CATAATGGCCGTCGACCACATGTGTGAGAGGGGCA-3’; Oct4 F 5’41

ATAGACCGGTAATGGCGGGACACCTGGC-3’, R 5’CATAATGGCCGTCGACCAGTTTGAATGCATGGGAGA-3’; b-Actin, F
5’-CTCTTCCAGCCTTCCTTCCT-3’, R 5’-AGCACTGTGTTGGCGTACAG-3’.
The Real-Time PCR reaction consisted of Cycle 1: 1 repeat at 94˚C for 5
minutes, Cycle 2: 45 repeats of step 1 at 94˚C for 30 seconds, step 2 at a
gradient from 56.2-61.0˚C for 30 seconds, and step 3 at 72˚C for 45 seconds,
Cycle 3: 1 repeat at 72˚C for 5 minutes, Cycle 4: 1 repeat at 90˚C for 1
minute, Cycle 5: 90 repeats at 50˚C for 10 seconds with an increase in
temperature of 0.5˚C after each cycle starting with cycle 2, and Cycle 6: 1
repeat at 25˚C for 5 minutes. Data collection was enabled at the end of Cycle
2 and melting curve data collection was enabled at Cycle 5.

Immunocytotochemistry

Immunocytotochemical staining was performed using a primary and
fluorescent-conjugated secondary antibody protocol. Briefly, cultured cells
were washed in phosphate buffered saline (PBS) and fixed in a 4%
paraformaldehyde fixative solution for 20 minutes at room temperature. W hen
staining for BrdU incorporation, samples were treated with 2N hydrochloric
acid for 20 minutes then washed three times with PBS.
Samples were then incubated at room temperature in a blocking
solution of PBS supplemented with 5% donkey serum and 0.2% triton X for
one hour. Sections were subsequently transferred to a blocking solution
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containing the primary antibodies and incubated overnight at 4˚C. Primary
antibodies for the following targets were used: Nanog, Oct4, Sox2, BrdU,
BetaIII-tubulin, and GFAP. The following morning, sections were then washed
and incubated in a fluorescent-conjugated secondary antibody (1:500 dilution)
for 2 hours in the dark, at room temperature. Stained sections were then
washed three times with PBS and mounted on a glass slide using a mounting
medium containing DAPI to label the nuclei of the cells.

Results

Cells were isolated from either bulk tumor masses or a flush solution of
surgical aspirate fluid. Tissue culture isolation of GBM patient brain tissue
using a defined serum-free NSC media identified two general groups of cells
that form from these tissues. The first group consisted of non-adherent
spheroid-forming cells, while the second group consisted of cells forming a
monolayer in culture (Figure 7).
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Figure 7: Isolation of cell populations from patient tumor samples. Cells are
isolated from patient samples either by dissociating the bulk tumor mass using
surgical scalpels (a) or through centrifugation of the surgical aspirate solution
(b). Cells isolated from either approach produce populations of cells that are
adherent or form floating spheroids. The spheroids have the properties of
cancer stem cells while the adherent cells resemble the characteristics of
differentiated cells.
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Adherent cells were more heterogenous and had lower rates of
proliferation. Cells were treated with BrdU for 48 hours to measure
proliferation rates and stained using antibodies specific for either CD133 or
BrdU. Changes in morphology and the frequency of BrdU-positive cells were
observed between the spheroid and adherent cell cultures. Moreover, CD133
expression could be observed in both the spheroid-forming cells, even after 4
days in serum-differentiation media, as well as in some adherent populations
(Figure 8).

Figure 8: Expression of CD133 and BrdU staining between adherent and
floating stem cell cultures. Cells expanded and spheroids had higher BrdU
staining and enriched CD133 staining within the spheroid (A). Transferring
cells to differentiation media supplemented with 10% FBS for four days
reduced the frequency of BrdU-positive cells, but CD133 was still expressed
in some of the cells. (B) Although most adherent cells did not express CD133,
some positive cells could still be observed (C). Scale bar = 63μm.

Analysis of proliferation rates between patient tumor-derived cell lines
revealed distinct differences in proliferation rates, as determined by BrdUincorporation. Cells expanding as tumor spheroids had significantly higher
rates of proliferation compared to adherent lines or tumor spheroids placed in
differentiation media. (Figure 9) In fact, following just four days in serum-
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supplemented media, proliferation rates in cancer stem cells were reduced by
half (p<0.001).

Figure 9: Proliferation rates measured by 48 hour BrdU-treatment Transferring
cancer stem cells in serum-supplemented media reduced the rates of
proliferation by 50% (p<0.001). After 48 hours, only 25% of adherent line 1
and 13% of adherent line 3 were positive for BrdU compared to nearly 80% of
cancer spheroids (p<0.0001).

Immunohistochemical staining also revealed differences between the
floating spheroid cultures, enriched for cancer stem cells, and the adherent
cell cultures. Spheroid cultures had a low frequency of expressing markers for
neuronal and astrocytic differentiation, as indicating with immunostaining for
βIII-tubulin and GFAP, respectively. However, neural spheres derived from
the primary tumors were enriched for neural stem cell markers, including Sox2
and Nestin (Figure 10).
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Figure 10: Expression of stem cell and differentiation markers in tumorderived stem cells. Tumor-derived cells grow as non-adherent spheroids
display low rates of GFAP and βIII-tubulin expression (A). Tumor spheroids do
readily express stem cell markers Sox2 (B) and Nestin (C). Adherent cell
cultures show stronger staining for neuronal differentiation markers (MAP2
and βIII-tubulin, D) as well as astrocytic markers (S100 and GFAP, E). Cancer
stem cells could be induced to express both neuronal (F) and astrocytic (G)
markers following one-week differentiation in media supplemented with
retinoic acid. Scale bar = 63μm.

Alternatively, adherent cell cultures displayed stronger staining for both
neuronal (βIII-tubulin and MAP2) as well as astrocytic (S100 and GFAP)
markers. The expression of these markers could be up-regulated following
one-week differentiation in media without EGF or FGF and supplemented with
retinoic acid.
The expression of neural stem cell markers by glioma-derived cancer
stem cells has been previously reported. However, we then tested if gliomaderived cancer stem cells express embryonic stem cell markers. Using stem
cell gene specific primers, we compared the expression of embryonic stem
cell markers nanog, sox2, oct4, and telomerase reverse transcriptase (TERT)
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of cancer stem cells to the adherent non-stem cell cultures and normalized
gene expression to beta actin (Table 1).

Table 1
PCR Analysis of Clones Resistant to Differentiation Relative to Normal Tumor
Non-neurosphere Cells
Relative gene expression
Nanog

142.51797

Sox2
Oct4

25.0198286
2,069.40456

Tert
Β-Actin

11.7533491
1

Note. Gene expression levels are normalized against beta-Actin gene
expression level.

In order to investigate the specificity of nanog as a cancer stem cell
marker, we compared the expression of nanog from multiple experiments to
the gene expression level of nanog from fetal-derived neural stem cells. We
found that cancer spheroids have elevated expression of nanog relative to
fetal neural stem cells (Table 2).
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Table 2
Nanog CT Values for GBM Tumor Clones
RT-PCR experiment

CT value

80616

22.1433

80229

22.8033

80802

23.09

80808

24.6133

80301

25.5267

80709

25.99

80517

27..603333

80821

27.366667

Fetal human NS cell

27.73333

Note. Fetal-derived neural stem cells have relatively lower nanog expression
then culture of spheroids derived from glioma tumors, as determined by Ct
threshold values.
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Although tumor-derived stem cells typically had higher nanog
expression, indicated by lower Ct values, the values varied between samples.
This reflects the heterogeneity of initial stem cell cultures and the need to
establish clonal-derived cell lines. Moreover, it suggests that within the tumor
mass, subpopulations of non-cancerous neural stem cells reside and can be
isolated.
We then carried out immunohistochemical staining to demonstrate that
the up-regulation of gene expression translates to strong protein staining. We
demonstrated the cancer stem cells stain positive for antibodies against
Nanog, Oct4, SSEA4 and CD133 (Figure 11).

Figure 11: Expression of embryonic stem cell markers in cancer spheroids.
Sphere forming cells express embryonic stem cell markers Nanog, SSEA4,
Oct4 and CD133.
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The expression of embryonic stem cell markers in glioma stem cells
provides an important differential marker that can serve to distinguish cancer
stem cells from non-cancerous neural stem cells.

Discussion

We were able to demonstrate that despite the heterogeneity of tumorderived cell lines, distinct populations of cells can be derived based on growth
properties. Specifically, cancer stem cells show greater proliferation and
express a unique set of markers that are not highly enriched in the adherent
cells comprised of cell from the bulk of the tumor. However, tumor stem cell
lines derived had varying levels of embryonic stem cell markers. Gene
expression analysis revealed tumor spheroids had significantly higher levels
of embryonic stem cell genes including Nanog, Oct4, and Sox2. Although
Sox2 is required for neural stem cell maintenance, the expression of Nanog
and Oct4 was unexpected since previous reports suggest they are not
expressed in human neural stem cells. Of the two cell types within the tumor
spheroids, those resistant to differentiation had much higher levels of Nanog
expression than those that proceeded to differentiate into neural and astroglial
lines. This suggests that the high expressing Nanog cells may represent true
CSCs while cells that express nanog at low concentrations, if at all, may be
infiltrating normal CSCs that migrate to the tumor tissue.
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Conclusions

The characterization of cancer stem cells is important from a
therapeutic and diagnostic standpoint. The ability of identify unique markers
that are enriched in cancer stem cells will lead to novel therapeutic targets.
Also, given the role of cancer stem cells in drug resistance and malignancy,
these markers may serve as diagnostic markers that can provide insight into
the best treatment options for the patient. However, the similarity between
brain tumor cancer stem cells and normal endogenous neural stem cells
poses a challenge. Elimination of endogenous neural stem cells may
contribute to post-chemotherapy cognitive impairment[161, 162] and the use
of neural stem cells and vehicles for anti-tumor therapies[144, 145, 156]
requires quality control measures to insure transplanted cells have not been
transformed during expansion.[163] Given that populations of neural stem
cells and cancer stem cells grow as non-adherent tumor spheroids and
express CD133, neither is a reliable way to differentiate tumor from non-tumor
stem cells within a GBM tumor. Our results suggest that the tumor spheroids
derived from GBM brain tissue do contain different stem cell populations,
which can be distinguished by the level of embryonic stem cell gene
expression. Nanog , a transcription factor critically involved with self-renewal
of undifferentiated stem cells seems to be the most differentially expressed in
these glioma stem cells. It’s levels in normal NS cells and differentiated tumor
cells are negligible. From our results, it seems that Nanog might be a better
CSC marker than the previously described CD133. Nanog, is thought to play
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a key role in maintaining pluripotency. Loss of Nanog function causes
differentiation of embryonic stem cells into other cell types and Nanog overexpression enables stem cell propagation for multiple passages during which
they remain pluripotent. Interestingly, p53 binds to Nanog’s promoter and
suppresses its expression resulting in stem cell differentiation.[164, 165]
Since Nanog is known to prevent differentiation of embryonic stem
cells, a similar mechanism may be preventing differentiation of the CSCs.
Future research studying Nanog’s role in regulating GBM tumor stem cell
differentiation and ways to block Nanog’s effects on these cells may allow for
therapies that enhance our ability to successfully treat patients with GBM
tumors.
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CHAPTER THREE:
CHARACTERIZATION OF CANCER STEM CELLS WITHIN
GLIOBLASTOMAS AND THEIR INHIBITION WITH HISTONE
DEACETYLASE INHIBITORS

Rationale

The signalling pathways that regulate stem cell self-renewal and
pluripotency are likely to have significant implications to cancer research for
several reasons. Transplantation of embryonic stem cells form taratomas
when transplanted but differentiated cells do not. Induced pluripotent cells
also have the capacity for tumorigenic transformation and forced expression
of the gene c-Myc, a gene critical for stem cell proliferation, facilitates
transformation of astrocytes to generate tumors with an undifferentiated
phenotype.[116] Our previous study has demonstrated the critical role of
nanog to expand the developmental potential of human mesenchym al stem
cells to pluripotent cells capable of neural differentiation. In this study, we
examine the role of embryonic stem cell genes in tumor-derived stem cells
and posit that their differential expression in cancer stem cells make them
attractive diagnostic and therapeutic markers.
Cancer stem cells are highly tumorigenic and resistant to
chemotherapy and radiation. We previously identified to role of embryonic
stem cell genes in distinguishing these cancer stem cells, but how these
genes are distinguished from cells comprising the bulk of the tumor has not
been examined. We hypothesize that these stem cell genes are critical to the
54

tumorigenic process and their expression correlates with malignancy.
Furthermore, we establish a new culturing method of isolating cancer stem
cells from the surgical flush and identify histone deacetytase inhibitors as
promising therapeutic options to target cancer stem cells.

Chapter Summary

Glioblastoma multiforme tumors are highly malignant brain tumors with
limited effective treatment options. Within these tumors, a subpopulation of
cancer cells with stem cell properties, have been shown to be extremely
resistant to radiation and current chemotherapeutic agents, and have the
ability to readily reform tumors. Therefore, the characterization of cancer stem
cells and the development of therapeutic agents that effectively target them
are extremely important.
In this study, we characterize these so-called cancer stem cells based
on gene expression using quantitative real-time PCR and
immunohistochemical staining for stem cell markers. We successfully isolated
cancer stem cells from both the bulk of the tumor and the surgical aspirate
fluid, demonstrating a new isolation technique and showing heterogeneity of
stem cells within the tumor. Moreover, we examined the effects of histone
deacetylase inhibitors trichostatin A (TSA) and valproic acid (VPA) on the
proliferation and gene expression profiles of cancer stem cells.
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Cells expanded in stem cell cultures expressed both neural and
embryonic stem cell markers Nanog, Oct4, Sox2, SSEA4, and CD133. Gene
expression analysis showed significant enrichment of these markers in cancer
stem cell cultures relative to cells grown in serum-supplemented media.
Transferring cancer stem cells to serum-supplemented media reduced
proliferation rates and greatly diminished expression of stem cell markers.
The histone deacetylase inhibitors TSA and VPA were effective at inhibiting
the proliferation of cells and down-regulating cancer stem cell markers.
This study characterizes the expression of multiple embryonic stem cell
markers in glioblastoma-derived stem cell lines. Furthermore, we demonstrate
the effectiveness of histone deacetylase inhibitors TSA and VPA at
significantly inhibiting cancer stem cell growth and down-regulation of stem
cell markers.

Introduction

Glioblastoma multiforme (GBM) tumors are aggressive gliomas that
demonstrate strong resistance to currently available chemotherapy options
and frequent recurrence following treatment. After diagnosis, median survival
times of GBM patients have been reported to be 20 weeks with surgery alone,
or up to 36 weeks if combined with radiation therapy.[118-121, 166] Median
survival times may be increased to nearly 15 months if either over 98% of the
tumor is removed[122] or chemotherapy is integrated with surgery and
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radiation treatment.[123, 124, 167] Unfortunately, this offers only a slight
improvement relative to the average survival span of 44-52 weeks
documented over 80 years ago.[125]
The heterogeneity of these GBM tumors, and particularly the presence
of a subpopulation of cancer stem cells within them, is believed to be critical
to the tumorigenic process.[131-136] Earlier studies have demonstrated the
existence of a subpopulation of cancer stem cells, identified as testing positive
for the surface marker CD133, within glioblastoma tumors that are able to give
rise to new tumors following transplantation into nude mice.[133-135, 143,
159, 168-170] Cancer cells that are negative for CD133 did not appear to form
tumors upon transplantation nor share stem cell characteristics observed in
CD133+ cells.[134, 135] These CD133-positive cancer stem cells have been
compared to human neural stem cells for both their growth properties and
gene expression.[134, 138, 143, 159, 171]
The ability for cancer stem cells to undergo tumorigenesis, in
conjunction with the resistance these cells have for radiation and
chemotherapy,[160, 172-175] is of particular clinical importance given the
propensity of gliomas to re-emerge following treatment. This study
characterizes different cell populations based on growth properties and shows
the existence of a distinct subpopulation of cells with cancer stem cell
properties. We characterize these cells based on their expression of stem cell
markers and demonstrate the effectiveness of histone deacetylase inhibitors
trichostatin A and valproic acid at inhibiting their growth.
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Materials and Methods

Cell Culture and Isolation

Human glioblastoma cells were removed from patients undergoing
treatment surgery who have provided informed consent for the study.
Surgically removed tumor specimens were washed, minced, dissociated, and
then plated inside a 75cm2 tissue culture-treated flask containing resuspension medium of DMEM/F12 (Invitrogen) supplemented with 10% fetal
bovine serum (FBS, Gibco) within an hour of surgery. Following an initial
expansion in a monolayer, the tumor cells were switched to a defined serumfree NSC media consisting of DMEM/F12 supplemented with 2% B27 (Gibco),
1% antibiotic/antimycotic (Gibco), 9U/ml of heparin (Sigma), 20ng/ml of basic
fibroblast growth factor (FGF-2, R&D Systems) and 20ng/ml of epidermal
growth factor (EGF, R&D Systems) to generate neural sphere formation at
different time points using non-tissue culture-treated suspension flasks and
plates. Specifically, cells were placed directly in neural stem cell media or
switched at 24, 48, or 72 hours. This culturing system generated cells with two
distinct growth properties, adherent cells and floating sphere-forming cells.
Adherent cells are likely differentiated tumor cells with limited proliferative
potential, whereas floating neural spheres contain multipotent stem cells.
Adherent cells were expanded by enzymatic dissociation (Accumax,
Innovative Cell Technologies); suspension cells were dissociated by quartersectioning with the razor blade [176] or pelleted and dissociated with 0.5ml of
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Accumax and gentle up-and-down pipetting for 5 minutes. Using quantitative
real-time PCR, cells were analyzed, for expression of neural stem cell genes,
stem cell transcription factors, tumor cell markers, and genes associated with
neural and glial differentiation. Additional characterization included
differentiation in serum supplemented media and antibody staining with stem
cell and neural lineage markers.

Isolation of Cells from Surgical Aspirate

Surgical aspirate samples were collected during routine procedures to
remove GBM tumors. The brain tissue was separated from the red blood cells
by successive gradient purification (four times) through centrifugation at 300g
using DMEM. The red blood cells formed a distinct layer that allowed for
easier isolation of cells from the tumor. Cells were then placed in T75
adherent and suspension culture flasks and cultured overnight in DMEM
supplemented with 10% FBS and 1% antibiotic/antimycotic. The following
day, cell culture media was collected and centrifuged at 200g three times
using DMEM to collect the pellet of nucleated cells, while separating out most
of the remaining red blood cells. The media was then changed to neural stem
cell media to facilitate the generation of spheroids. Once spheroids were
generated, they were cultured in suspension flasks to reduce the occurrence
of spontaneous differentiation. The adherent cells, when nearing confluence,
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were enzymatically-dissociated and expanded into new flasks at a 1:2 dilution
in cell culture media.

Culturing of Human Neural Stem Cell Lines

Two different human neural stem cell lines were used to compare
growth properties and to serve as a positive control for immunostaining. Fetalderived human neural progenitor cells (Lonza) were grown in suspension and
expanded. Additionally, an adherent immortalized tumor cell line, ReNcell CX
(Millipore) was grown in flasks pre-coated with laminin in non-serum stem cell
media.[177, 178]

Generation of Clonal-Derived Cancer Stem Cell Lines

To generate clonal-derived cancer stem cell lines, we dissociated
cancer spheroids and plated individual cells inside wells of a 96-well plate.
Wells that received multiple cells were excluded from further culturing.
Individual cells that re-grew colonies were then selected and passaged again
in single cell cultures inside a 96-well plate to insure that spheroids were
indeed clonally derived. This process was followed for cancer stem cells
isolated from both the tumor mass and the surgical aspirate.
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RNA Isolation and Quantitative Real-Time PCR

Cell culture media was removed from cells and RNA extraction was
performed using a commercially available TRIZOL reagent (Invitrogen). RNA
concentrations were measured using spectrophotometry. Gene expression
was measured by quantitative real-time PCR (qRT-PCR) using gene specific
primers. Primers were designed using commercially available software[179]
(Oligo 6.8, Molecular Biology Insights, Cascade, CO) and freely available
online programs (Primer3 and Primer3 Plus).[180, 181] Given the high
variability of “housekeeping genes,” [182-187] we tested multiple
housekeeping genes (β-actin, GAPDH, and HPRT) and β-actin showed the
least variation in our preliminary testing studies (data not shown). Our
optimization results are supported by studies that suggest GAPDH and HPRT
activity may be altered in tumors because of mutations, altered regulation or
treatments.[182, 186-192] Primers were tested for optimal annealing
temperature, efficient application of the target sequence, and single product
formation. Primers that formed multiple products-such as primer dimerizationas indicated by melt curve analysis and gel electrophoresis, were not used for
qRT-PCR analysis. However, two different sets of nanog primers, spanning
different exons, were used to determine if a splice variant was formed. No
variant was observed.

61

Cell Differentiation

Expanded human neural stem cells or tumor-derived spheroids were
cultured in serum-free basal media supplemented with a 1%
antibiotic/antimycotic solution for one week to assess differentiation.[193] Alltrans retinoic acid (Sigma) at a 1μM concentration was supplemented in some
cultures to enhance differentiation in serum-free conditions.[194-196]
Alternatively, serum-induced differentiation was performed using serumsupplemented (10% FBS) DMEM, each containing 1% antibiotic/antimycotic
solution in tissue culture treated plates.

Drug Treatments

Histone deacetylase inhibitors (HDACi) Valproic acid (VPA) and
trichostatin-A (TSA) stocks were prepared by dissolving the compounds in
ethanol and then diluted to working stocks. The total ethanol concentration
treated for cell cultures was less than 0.1% and did not affect cell growth.
Control cells consisted of treatment with the same percentage of ethanol.

Immunohistochemical Staining

Immunohistochemical staining was performed using a primary and
fluorescent-conjugated secondary antibody protocol. Briefly, cultured cells
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were washed in phosphate buffered saline (PBS) and fixed in a 4%
paraformaldehyde fixative solution for 20 minutes at room temperature. When
staining for BrdU incorporation, samples were treated with 2N hydrochloric
acid for 20 minutes then washed three times with PBS. Samples were then
incubated at room temperature in a blocking solution of PBS supplemented
with 5% donkey serum and 0.2% triton-X for one hour. Sections were
subsequently transferred to a blocking solution containing the primary
antibodies and incubated overnight at 4°C. Primary antibodies for the
following targets were used: Nanog (1:500, Ab9220, Chemicon), Oct4 (1:500,
MAB4401, Chemicon), Sox2 (1:500, Ab5603, Chemicon), BrdU (1:200,
Ab6328, Abcam), βIII-tubulin (1:1000, T8660 and T2200, Sigma), and GFAP
(1:1000, G9269 and G3893, Sigma), CD133 (1:100, Ab16518, Abcam), MAP2
(1:500, Ab5622, Abcam), MCM2 (1:500, Ab6153, Abcam), SSEA4 (1:500,
MAB4304, Chemicon), Nestin (1:500, MAB353, Chemicon).
The following morning, sections were then washed and incubated in a
fluorescent-conjugated secondary antibody (1:500 dilution) for 2 hours in the
dark at room temperature. Stained sections were then washed three times
with PBS and mounted on a glass slide using a mounting medium containing
DAPI to label the nuclei of the cells.
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Microscopy

Cells were analyzed using an inverted Leica microscope with a
mounted camera using Openlab 4.0 software (Improvision). Negative controls
consisting of fixed cells immunostained without incubation with secondary
antibodies were used to rule out auto-fluorescence or non-specific binding.
Cell imaging was done using the same camera settings and exposure range
for each sample. Images were then saved as TIFF files and combined in
Photoshop as RBG images. Multiple samples were photographed and cells
were counted and examined. Quantitative analysis of cell numbers was
performed by counting of blindly-selected regions in multiple samples using
Photoshop.

Statistical Analysis

Data was compiled in Microsoft Excel and GraphPad Prism software
and statistical analysis was carried out using a minimum of three independent
samples and graphed using the mean and standard deviation. Real-time PCR
data was analyzed based on comparison of normalized Ct values. [50, 51,
184, 197] Although previous studies by our lab have relied on visual
estimations of relative gene expression[113, 114] or employed a standard ttest for statistical analysis,[198, 199] we employed a t-test for unequal
variance. The Student t-test holds true for data that has a normal
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distributions,[200, 201] while the test used for these experiments does not
assume equal variance.[202, 203] This new approach overcomes problems
with the conventional t-test for gene expression analysis[51, 184, 204, 205]
and does not require testing for normality,[202, 203] a required step that
typically is not carried out. To further validate the appropriateness of this
approach, we carried out an F-test demonstrating that our gene expression
data does not follow a normal distribution. Cell counting was performed on
blindly-selected regions that were photographed from at least three
independent wells. Cell count data was analyzed for One-way ANOVA using
Bonferroni multiple comparisons post-hoc testing.

Results

Isolation of Cancer Stem Cell Lines

We attempted to generate cancer stem cell and non-stem cell lines
from both the mass of the tumor and the surgical flush. Two distinct cell
populations were generated from culturing cells in serum-supplemented or
serum-free media. Cells cultured in conventional serum-supplemented media
adhered to the flask and displayed heterogenic morphology-typically with
branched spindle-like processes and high nuclear to cytoplasmic ratios,
(Figure 12, A1) which is consistent with observations by multiple groups.[128,
206-209] Contrastingly, when cultured in serum-free conditions, cells grew in
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suspension forming spheroids (Figure 12, A2). Although serum-free
conditions did exhibit adherent cells, they were relatively non-proliferative, and
by the third passage, cultures consisted almost entirely of suspended cells
resembling neural stem cell spheroids.(Figure 12) Serum-free culturing
conditions and samples that were generated from the surgical flush had
significantly more cellular debris compared to serum-supplemented cultures of
cells generated from the tumor mass, simply because the floating debris is
easily removed when changing the media of adherent cells (Figure 12, A3-4).
Floating stem cell cultures required additional low-speed centrifugation to
separate the smaller pieces of debris and residual red blood cells.
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Figure 12: Morphology of cells in culture. Dissociation of tumor tissues can
produce two distinct cell populations, adherent cells that grow in a monolayer
in serum-supplemented culture (A1) or cells that grow in suspension in NSC
culture conditions (A2). Cells isolated from the surgical flush are also give rise
to monolayer (A3) and spheroid-growing cells (A4), in serum-supplemented
and NSC culture media, respectively. More cellular debris is present with
surgical aspirate-derived cultures. Cells grown in serum-supplemented (B1)
and serum-free stem cell media (B2) maintain their growth patterns in
continuous culture (5 weeks). Tumor-derived cells expanded in serum-free
stem cells cultures resemble fetal-derived non-cancerous stem cells (B3).
Scale bar = 63μm.
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Nonetheless, by two to three weeks, floating spheres were generated
from either cell source and were easily expanded by passaging and reseeding in new suspension flasks. The initial passaging of the cancer stem
cells produced floating and adhering cells, suggesting that early passaged
cells still contain non-stem cells or are still prone toward spontaneous
differentiation. However, after one month of continuous culture, cell cultures
were less heterogeneous-with retracted cytoplasmic processes compared to
serum-cultured cells-and began to readily expand (Figure 12, B1-2). The stem
cell cultures produced proliferating spheroids (Figure 12, B2) that resembled
human fetal-derived neural stem cells Figure 12, B3). We also examined
slight variations in culturing conditions to determine the optimal approach to
generating cancer spheroids. We compared the culturing of cells after
immediate plating in stem cell media to transference after 24, 48, and 72
hours from serum-supplemented media.
Surprisingly, initial culturing with only neural stem cell media produced
very few viable neural spheres; culturing in serum media for 48 hours also
resulted in a limited number of slow proliferating spheres; and, no spheroids
were generated in cultures that were initially treated with serum media for 72
hours. Culturing cells in serum media overnight prior to transferring to neural
stem cell media yielded the most spheroids. Hence, given the time points
tested, the optimal time to transition to neural stem cell media is 24 hours
post-plating.
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Characterization of Cancer Stem Cell Lines Based on Immunohistochemistry

We compared the expression of multiple stem cell markers among the
adherent serum-supplemented cell cultures, the tumor spheroids, and an
immortalized neural stem cell line, ReNcell CX. The immortalized neural
progenitor cell line ReNcell Cx grows as an attached monolayer in plates precoated with laminin. Incubation of fixed samples with only secondary
antibodies conjugated with either FITC or TRITC revealed no detectable nonspecific binding or auto-fluorescence (Figure 13, A). The immortalized stem
cell line shows positive immunostaining for the early neuronal and astrocytic
markers βIII-tubulin (Figure 13, B2) and GFAP (Figure 13, B3), respectively.
The ReNcell Cx cells were also positive for stem cell markers Nestin (Figure
13, C2),
CD133 (Figure 13, C3), MCM2 (Figure 13, D2), and Sox2 (Figure 13,
D3). However, this line showed no appreciable staining for embryonic stem
cell markers Oct4 (Figure 13, E2) and Nanog (Figure 13, E3).
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Figure 13: Expression of stem cell and lineage markers in the ReNcell Cx line.
The immortalized neural progenitor cell line ReNcell Cx grow as an attached
monolayer in plates pre-coated with laminin. Fixed cells were treated with
DAPI to stain the nuclei (A-E4). They do not show positive staining when
stained with secondary antibodies conjugated with either FITC (A2) or TRITC
(A3). They do demonstrate expression of lineage markers βIII-tubulin (B2) and
GFAP (B3) as well as neural stem cell markers. ReNcell Cx cells also have
positive staining for Nestin (C2), CD133 (C3), MCM2 (D2), and Sox2 (D3).
However, the neural stem cell line does not stain positive for the embryonic
stem cell markers Oct4 (E2) or Nanog (E3). Scale bar = 63μm.
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Adherent tumor-derived cells grown in serum-supplemented media do
not appreciably express stem cell markers CD133 (Figure 14, A2) or Oct4
(Figure 14, A3). However, cells do demonstrate strong expression of the
mature neuronal marker MAP2 (Figure 14, B2) as well as the early lineage
marker βIII-tubulin (Figure 14, B3). The cells also have strong expression of
glial differentiation markers S100 (Figure 14, C2) and GFAP (Figure 14, C3).
The expression of differentiation markers is consistent with their differentiated
spindle morphology.

Figure 14: Expression of stem cell and lineage markers in adherent tumorderived cells. Adherent tumor-derived cells grown in serum-supplemented
media do not appreciably express stem cell markers CD133 (A2) or Oct4
(A3). However, cells do demonstrate strong expression of the mature
neuronal marker MAP2 (B2) as well as the early lineage marker βIII-tubulin
(B3). The cells also have strong expression of glial differentiation markers
S100 (C2) and GFAP (C3). Scale bar = 63μm.
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Glioma stem cells, expanded in serum-free and growth factorsupplemented stem cell media, did positively stain for neural and embryonic
stem cell markers, as well as for markers of differentiation. Tumor spheroids
express neural stem cell markers CD133 (Figure 14, A2 and 15, E2), Nestin
(Figure 15, B2), transcription factor Sox2 (Figure 15, B3 and 15, D2) and
proliferation marker MCM2 (Figure 15, E3). Moreover, the spheroids were
also immunopositive for embryonic stem cell markers Nanog (Figure 15, C2),
Oct4 (Figure 15, A3), and SSEA4 (Figure 15, C3). However, cells were
negative for embryonic stem cell surface marker TRA-1-60 (Figure 15, D3).
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Figure 15: Expression of stem cell markers in tumor-derived stem cells.
Tumor-derived cells grow as non-adherent spheroids express stem cell
markers CD133 (A2, E2), Oct4 (A3), Nestin (B2), Sox2 (B3, D2), Nanog (C2),
SSEA4 (C3) and MCM2 (E3), but not surface marker TRA1-60 (D3). Scale
bar = 63μm.
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GBM stem cells also expressed low levels of early lineage markers βIIItubulin (Figure 16, A3 and 16B3) and GFAP (Figure 16, A2 and 16, C3). The
tumor-derived stem cells were also weakly positive for differentiation markers
MAP2 (Figure 16, B2) and S100 (Figure 16, C2). Although spheroids were
comprised of cells that were positive for both neuronal and glial markers, two
different lineage markers were typically not expressed within the same cell.
We also found cancer stem cells to have higher rates of proliferation relative
to serum differentiation-induced cells and adherent non-stem cell cultures.
Moreover, when differentiation is induced in the cancer stem cells, we
observe the loss of stem cell markers and an increase in markers of
differentiation.

Figure 16: Expression of lineage markers in tumor-derived stem cells. The
cells also expressed developmental markers for neuronal (βIII-tubulin (A3)
and MAP2 (B2)) and glial (GFAP (A2, C3), S100 (C2)) lineage differentiation.
Scale bar = 63μm.
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Gene Expression Analysis of Cancer Stem Cell Lines

We next examined the relative differences in gene expression profiles
among three different cell lines, two of which were generated from two
different sources (tumor mass and surgical flush) from the same patient (AA102 and AA1-06). We measured consistently higher expression of genes
critical to stem cell proliferation and self-renewal in the glioma stem cells
relative to the adherent non-stem cell cultures. Cancer spheroids derived from
either the bulk of the tumor tissue (CSC AA1-02 and CSC AA3-01) or the
surgical flush (CSC AA1-06) demonstrate enriched expression of stem cell
markers and other genes compared to adherent tumor cells expanded in
serum-supplemented cultures. Cancer stem cell line AA1-02 showed elevated
expression of GAPDH (4.2x, p<0.01) and stem cell transcription factors nanog
(99.1x, p<0.0001), oct4 (9.3x, p<0.01), and sox2 (1341x, p<0.00001). Cell line
CSC AA1-06 has enhanced relative expression of stem cell markers nanog
(20.9x, p<0.0001) and sox2 (461.2x, p<0.00001). Telomerase reverse
transcriptase (TERT) and telomeric repeat-binding factor 1 (TERF1) were
both significantly higher in both cancer stem cell lines (TERT: 129.0x and
682.1x, p<0.001 and p<0.001; TERF1: 8.8x and 1.6x, p=0.01 and 0.01,
respectively).

75

Figure 17: Cancer spheroids have enhanced stem cell gene expression
patterns. Cancer spheroids derived from either the bulk of the tumor tissue
(CSC AA1-02 and CSC AA3-01) or the surgical flush (CSC AA1-06)
demonstrate enriched expression of stem cell markers and other genes
compared to adherent tumor cells expanded in serum-supplemented cultures.
Cancer stem cell line AA1-02 showed elevated expression of GAPDH and
stem cell transcription factors nanog, oct4, and sox2. Cell lines CSC AA1-06
and CSC AA3-01 show enhanced expression of stem cell markers nanog and
sox2. Telomerase reverse transcriptase (TERT) and telomeric repeat-binding
factor-1 (TERF1) were both significantly higher in the cancer stem cell lines.
The stem cell genes that showed the greatest differential expression were the
stem cell transcription factors nanog and sox2 along with tert and surface
marker CD133. Statistical significance indicated by asterisks: *p<0.05,
**=p<0.01, ***p<0.001, ****p<0.0001.
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The presence of active telomerase functioning is commonly observed
in many tumors, but is extremely low in adult neural stem cells and glioma
cells expanded in serum-supplemented cultures. The gene Lefty, which
regulates both embryonic stem cell expansion and early neuroectoderm
differentiation,[210-213] was not statistically enhanced nor decreased in either
the AA1-02 (p=0.35) nor the AA1-06 (p=0.10) line. However, the surface
marker CD133 appears to have the greatest discrepancy in expression
between the adherent tumor cells and tumor spheroids in CSC lines AA1-02
(4748.6x, p<0.01) and AA1-06 (926.9x, p<0.01).
Cancer stem cell line AA3-01 has robust over-expression of the
embryonic stem cell transcription factors nanog (74.1x, p<0.0001), oct4
(15.8x, p<0.001), and sox2 (106.3x, p<0.0001) relative to adherent serum supplemented cell cultures. This cell line also expressed higher levels of tert
(21.1x, p<0.01), terf1 (16.2x, p=0.058), and lefty (71.2x, p<0.05). CD133, as
expected, had significantly greater relative expression in the AA3-01 line as
well (588.4x, p<0.01).
The gene expression levels between the tumor mass-derived (AA1-02)
and surgical flush-derived (AA1-06) cell lines was significantly different for
almost all genes tested. Cell line AA1-02 showed greater relative expression
levels of GAPDH (p<0.01), oct4 (p<0.05), sox2 (p<0.001), terf1 (p<0.05), lefty
(p<0.05), and CD133 (p<0.05) when compared to the AA1-06 line. Although
the relative expression of tert was enhanced in the AA1-06 line (p=0.01).
Relative expression levels of nanog were not statistically different between the
two lines (p=0.11).
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Differentiation Analysis of Cancer Stem Cell Lines

Cancer stem cells were similar to healthy neural stem cells with respect
to morphology, a non-adherent spheroid growth pattern, and the ability to
differentiate into neural and glial progenitors, as indicated by βIII-tubulin and
GFAP immunostaining. However, cancer stem cells were more resistant to
differentiation, particularly when the tumor spheroid was intact. Human fetalderived neural stem cells underwent differentiation when transferred to a
serum-free and non-growth factor-supplemented basal cell culture medium
(Figure 18, A). Cells, grown as neural spheres, attached and differentiated
along both neuronal (βIII-tubulin, Figure 18, A1) and glial (GFAP, Figure 18,
A2) lineages. Following one week of culturing in basal media, neural stem
cells developed a differentiated morphology with extensive cellular processes
(Figure 18, A). When the cancer spheroids were transferred to serum-free
differentiation cultures, the cells attached and displayed enhanced expression
of (βIII-tubulin, Figure 18, B1) and glial (GFAP, Figure 18, B2). However, the
glioma stem cells were far more resistant to differentiation, particularly when
the spheroid remained intact. (Figure 18, B) Serum-free differentiation failed
to eliminate the expression of stem cell markers within the spheroid. After one
week, cancer stem cells still maintained the expression of CD133 (Figure 18,
C1) and Oct4 (Figure 18, C2). The use of retinoic acid, an enhancer of
differentiation, was still ineffective at eliminating the expression of stem cell
markers (Figure 18, D).
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Figure 18: Differentiation of cancer spheroids. Human neural stem cells
undergo differentiation when transferred to a serum- and growth factor-free
basal medium. Following one week of differentiation in non-supplemented
basal cell culture media, neural stem cell spheroids adhered to the plate and
migrated outward, increasing the expression of βIII-tubulin (A1) and GFAP
(A2), cancer spheroids also expressed βIII-tubulin (B1) and GFAP (B2), but
were more resistant to differentiation. Cancer spheroids still expressed stem
cell markers CD133 (C1) and Oct4 (C2) after one week of basal media
differentiation. Moreover, the expression of both stem cell markers persisted
even when cultured in basal media supplemented with retinoic acid (D1-3).
The use of serum-supplemented media was used to induce differentiation of
tumor spheroids (E1-4). Following four days of serum-induced differentiation,
differentiating cells migrated away from the spheroid and had more intense
staining for βIII-tubulin (E1), but lower staining for CD133 (E2), Sox2 (E3), and
Nanog (E4). Serum-induced differentiation also significantly decreased
proliferation and Sox2 expression. Scale bar = 63μm. Statistical significance
indicated by asterisks: *p<0.05, **=p<0.01, ***p<0.001, ****p<0.0001.
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Culturing gliomas stem cells in serum-supplemented media did
facilitate differentiation. Following four days of serum-induced differentiation,
cells migrated away from the spheroid and had more intense staining for βIIItubulin (Figure 18, E1). CD133 expression was still maintained within the
intact spheroid, but was not readily detected in the differentiating cells outside
the adhered spheroid (Figure 18, E2). Stem cell transcription factors Sox2
(Figure 18, E3) and Nanog (Figure 18, E4) were detected in the spheroid, but
only Sox2 expression was observed in the differentiating cells.
Serum-induced differentiation has a significant impact on both the rate
of proliferation and expression of stem cell markers (Figure 18, F).
Proliferation, as indicated by BrdU-positive staining, showed a significantly
decrease in the serum-induced differentiation cultures (22.8%, SD=0.05)
compared to the non-differentiated control spheroids (77.8%, SD=11.6,
p<0.0001). Unlike Nanog, Sox2 was still commonly expressed in the
differentiating cells, albeit at a lower frequency compared to undifferentiated
cells (90.3%, SD=0.03 compared to 64.9%, SD=0.09, p<0.0001).
Rates of proliferation for the adherent and cancer stem cells in vitro
were measured by the incorporation of BrdU over a 48-hour period.
Immunohistochemical staining revealed a high rate of proliferation for cancer
stem cells relative to adherent cells. Specifically, cancer stem cells showed a
three to six times higher rate of proliferation relative to adherent cancer cells
in vitro. Following treatment, 78 percent of cancer stem cells were positive for
BrdU, as compared to 24.7 and 13.3 percent for two independent adherent
cell lines (p<0.001, data not shown).
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Effects of Histone Deacetylase Inhibitors on Cancer Stem Cell Lines

When differentiation is induced, proliferation rates and expression of
stem cell markers decrease. We therefore hypothesized that a drug that was
effective at inducing differentiation would be a promising glioma adjuvant
therapy. Although previous studies have demonstrated some anticancer
effects of histone deacetylase inhibitors, no one has investigated their effect
on glioma stem cells, which are highly resistant to all current
chemotherapeutic agents marketed for glioma therapies. We tested the
histone deacetylase inhibitors valproic acid and trichostatin A on gene
expression and proliferation of cancer stem cells.
Cancer stem cells proliferate rapidly in culture, yielding a high
frequency of BrdU-stained cells (Figure 8, A2) as well as robust staining for
CD133 (Figure 19, A4). Supplementing the stem cell media for 48 hours with
valproic acid (1mM) or trichostatin A (1μM) decreased the number of BrdUpositive cells (Figure 19, B-C2) and showed lower CD133 staining (Figure 8,
B-C3). Cells also appear to have more cellular processes after exposure to
either VPA (Figure 19, B) or TSA (Figure 19, C), indicating induction of
differentiation within a relatively short period of time.
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Figure 19: Histone deacetylase inhibitors alter glioma stem cell morphology.
Cancer stem cells proliferate rapidly in culture, yielding a high frequency of
BrdU-stained cells (A2) as well as robust staining for CD133 (A4).
Supplementing the stem cell media with valproic acid (VPA, 1mM) or
trichostatin A (TSA, 1μM) decreased the number of BrdU-positive cells (BC2)
and showed lower CD133 staining (B-C3). Cells also appear to have more
cellular processes after exposure to either VPA (B) or TSA (C), indicating
induction of differentiation. Scale bar =63μm.
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Treatment with 1mM valproic acid significantly reduced the rate of
glioma stem cell proliferation, decreasing the frequency of BrdU-positive cells
from 78% to 60% (Figure 20) (p<0.01). Exposure to trichostatin A had an even
more profound reduction in proliferation, reducing the frequency of cells that
underwent proliferation to 34% (p<0.001).

Figure 20: Valproic acid and trichostatin A reduce glioma stem cell
proliferation. Treatment with 1mM valproic acid significantly reduced the rate
of glioma stem cell proliferation, decreasing the frequency of BrdU-positive
cells from 78% to 60% (p<0.01). Exposure to trichostatin A had an even more
profound reduction in proliferation, reducing the frequency of cells that
underwent proliferation to 34% (p<0.001).

Treatment with histone deacetylase inhibitors valproic acid and
trichostatin A significantly lowered the expression of stem cell genes while
increasing the expression of lineage differentiation markers. Expression of
CD133 and nanog dramatically reduced when cultured with either VPA (88.0
and 99.8% reduction in CD133 and nanog, p<0.05 and p<0.0001,
respectively) or TSA (86.7% and 99.2%, p<0.05 and p<0.0001). Valproic acid
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inhibited oct4 expression (53.7% reduction, p<0.01), while TSA had a 71%
reduction in sox2 levels (p<0.01). The embryonic stem cell marker zfp342 was
abated by both drugs (76.2 and 70.1% reduction, p<0.01 and p<0.01).
Telomerase reverse transcriptase expression was diminished by both VPA
(54.6% reduction, p<0.01) and TSA (80.8% reduction, p<0.05), whereas
levels of terf1 were not significantly altered. Interestingly, there were no
changes in the levels of the apoptosis inhibitor Bcl-xL or its repressor Bcl-xs.
Culturing with the drugs did up-regulate differentiation markers βIII-tubulin
(VPA: 2.1x increase, p<0.01) and GFAP (VPA: 3.1x increase, p<0.01, TSA:
4.6x increase, p<0.01) (Figure 21).

Figure 21: Valproic acid and trichostatin A negatively regulate the expression
of stem cell genes. Treatment with histone deacetylase inhibitors valproic acid
and trichostatin A significantly lowered the expression of stem cell genes
while increasing the expression of lineage differentiation markers. Expression
of CD133 and nanog dramatically reduced when cultured with either VPA or
TSA. Valproic acid inhibited oct4 expression, while TSA reduced levels of
sox2. The embryonic stem cell marker zfp342 was abated by both drugs.
TERT was also diminished by both HDACi, whereas levels of terf1 were not
significantly altered. Interestingly, there were no changes in the levels of the
apoptosis inhibitor Bcl-xL or its repressor Bcl-xs. Culturing with the drugs did
up-regulate differentiation markers βIII-tubulin and GFAP.
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Discussion

Here we report the ability to generate cancer spheroids from the
surgical aspirate of glioblastoma surgeries. The derivation of multiple cell
populations from the surgical aspirate offers unique advantages compared to
relying on merely the tumor mass. The cells in the aspirate are more
disaggregated and avoid the need for extended mechanical dissociation
and/or enzymatic digestion. Additionally, viable recovery of multiple cell types
may allow for the recovery of healthy neural stem cells that migrate to the
tumor. Following rigorous quality control measures, these healthy cells may
be transplanted back to the patient to help facilitate recovery, or, given their
ability to migrate to tumors, used to deliver anti-tumor compounds.
Potential questions arise regarding differences between cells derived
from the tumor mass and those from the surgical aspirate-the later
presumably being partially comprised of healthy brain matter. Our studies
indicate, at least with respect to the cancer-derived spheroids, that both
populations resist differentiation and show rapid rates of proliferation.
Following expansion, we believe that there is a selective advantage with the
tumor cells relative to the healthy brain cells that are either non-proliferative or
display slow cell cycle kinetics. When comparing the two populations, their
gene expression profile is surprisingly similar when examining a host of stem
cell genes. These stem cells genes have been reportedly expressed in
malignant tumors at varying levels, but the similar profile suggests that the
spheroids derived from the mass and flush are similar in nature.
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Culturing conditions have a large impact on the generation of spheroids
in culture. Specifically, culturing cells for 24 hours in serum media produced
dramatically more spheroids than culturing directly in neural stem cell media
or continuing in culture beyond 24 hours. This skewed distribution suggests
that components within the serum may irreversibly change the fate of the
stem cells.
The effects of serum on the glioma cell cultures likely skew the cultures
in two distinct ways. First, serum induces differentiation of both noncancerous neural stem cells and glioma-derived stem cells. Therefore, serum
culture would quickly eliminate stem cell sub-populations through
differentiation. Second, serum-supplemented culture is a radically different
environment compared to the in vivo tumor environment. This change in
environment causes dramatic changes in gene expression within three
passages.[214] In fact, genomic profiling reveals that after only two weeks in
culture, seven out of eight glioma samples saw the genomic pattern in
adherent serum-based culture diverge from the parent tumor, whereas
spheroid suspension cultures preserved the genomic profile of the original
tumor.[215]
Gene expression analysis revealed tumor spheroids had significantly
higher levels of embryonic stem cell genes including Nanog, Oct4, and Sox2.
Although Sox2 is required for neural stem cell maintenance, the expression of
Nanog and Oct4 was unexpected since previous reports suggest they are not
expressed in neural stem cells. Our own analysis shows that both are not
appreciably expressed even in immortalized neural progenitor cell lines.
86

The higher expression levels of TERT in the cancer stem cell cultures
demonstrates the importance of telomerase activity in cancer stem cells and
supports the use of it as a clinical marker. However, the elevated expression
of TERF1 challenges reports that show TERF1 to be inversely correlated to
malignancy. These results, although unexpected, may be explained by three
potential hypotheses. First, cancer stem cells are a subpopulation within the
tumors, and the lower expression of TERF1 may be the result of a larger
percentage of non-cancerous cells comprising the glioma mass. Second, the
elevated levels of TERF1 within the cancer stem cells still may be lower than
the overall expression in lower grade tumors. Finally, the cancer stem cells
may be unresponsive to TERF1, thereby not being affected by higher relative
expression. The fact that TERF1 has almost no detection in non-tumor
tissues, [216] combined with our data showing no difference in expression
following HDACi treatment, suggests a combination of the second and third
theories.
Our study demonstrates a clear inhibitory affect of HDACi on glioma
stem cells. These data challenges other reports demonstrating an increase in
CD133 in gliomas cell lines following treatment with valproic acid and 5-aza2’deoxycytidine.[217] The authors use commonly available glioma cell lines
and convincingly demonstrate that treatment with 5-aza-C and VPA results in
promoter hypo-methylation and expression of CD133. However, upon closer
inspection of their data, their treatment had the opposite effect in their U87MG
cell lines. The U87MG line is unique from the other lines given the higher
basal expression of CD133. Moreover, the U87MG line is highly tumorigenic,
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readily forming tumors upon transplantation, whereas most glioma cell lines,
including the T98G line, are not.[218] The differences observed with the
U87MG line are particularly significant since it is the most well-characterized
gliomas line containing a sub-population of cancer stem cells.[185, 219-223]
Alternatively, the effects of HDACi may be dependent on p53 status,
but that study demonstrated that phenylbutyrate sensitizes glioma cell lines
with mutated p53 (U251 and SKMG-3) and did not affect wild-type cells (U87
and D54).[224]
Immunohistochemical staining showed positive staining for CD133 in
adherent and cancer spheroids. The expression of CD133 in both populations
of cells raises questions regarding its specificity for cancer stem cells. Tumor
spheroids and adherent cancer cells show CD133 positive and negative cell
populations, although the spheroids are largely positive. Earlier findings
suggest that populations of cancer stem cells are CD133 negative, as we
have observed. However, the expression of CD133 on the adherent cells,
which are far less tumorigenic, suggests that CD133 alone is not a sufficient
cancer stem cell marker and/or there is a morphologically distinct population
of cancer stem cells. The notable difference between CD133 expression
among adherent cell populations may be reflective of differences in the tumor
molecular profile, affects of treatment, or a reflection of the surgery.
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Conclusions

These markers, given their enrichment in cancer stem cells, may serve
as powerful diagnostic and prognostic markers for malignant tumors. The
systematic evaluation of these cancer stem cells is important in targeting them
for treatment by compounds that selectively induce cell death or make them
sensitive to chemotherapy. We demonstrate histone deacetylase inhibitors
are effective at inhibiting proliferation and reducing the expression of
malignant markers in GBM-derived stem cells, making them a promising
therapeutic option.
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